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Abstract 
 The Runx family of transcription factors supports cell fate determination, 
cell cycle regulation, global protein synthesis control, and genetic as well as 
epigenetic regulation of target genes.  Runx1, which is essential for 
hematopoiesis; Runx2, which is required for osteoblast differentiation; and 
Runx3, which is involved in neurologic and gut development; are expressed in 
the growth plate during chondrocyte maturation, and in the chondrocytes of 
permanent cartilage structures.  While Runx2 is known to control genes that 
contribute to chondrocyte hypertrophy, the functions of Runx1 and Runx3 during 
chondrogenesis and in cartilage tissue have been less well studied.   
 The goals of this project were to characterize expression of Runx proteins 
in articular cartilage and differentiating chondrocytes and to determine the 
contribution of Runx1 to osteoarthritis (OA).    Here, the expression pattern of 
Runx1 and Runx2 was characterized in normal bovine articular cartilage.  Runx2 
is expressed at higher levels in deep zone chondrocytes, while Runx1 is primarily 
expressed in superficial zone chondrocytes, which is the single cell layer that 
lines the surface of articular cartilage.  Based on this finding, the hypothesis was 
tested that Runx1 is involved in osteoarthritis, which is a disease characterized 
by degradation of articular cartilage and changes in chondrocytes.  These studies 
showed that Runx1 is upregulated in articular cartilage explants in response to 
mechanical compression.  Runx1 was also expressed in chondrocytes found at 
the periphery of OA lesions in the articular cartilage of mice that underwent an 
ix
OA-inducing surgery.  Runx1 was also upregulated in cartilage explants of 
human osteoarthritic knees, and IHC data showed that Runx1 is mainly 
expressed in chondrocyte “clones” characteristic of OA.  
 To ascertain the potential function of the upregulation of Runx1 in these 
cartilage stress conditions and disease states, the hypothesis was tested that 
Runx1 is upregulated in very specific chondrocyte populations in response to the 
cartilage damage in osteoarthritis.  These studies addressed the properties of 
these cells that related to functions in cell growth and differentiation.   In both the 
surface layer of normal articular cartilage, and in OA cartilage, Runx1 expression 
by IF co-localized with markers of mesenchymal progenitor cells, as well as 
markers of proliferation Ki-67 and PCNA.  This finding indicated that Runx1 is 
found in a population of cells that represent a proliferative population of 
mesenchymal progenitor cells in osteoarthritis.  
 To further address Runx1 function and identify downstream targets of 
Runx proteins, a promoter analysis of genes that are known to be either 
downregulated or upregulated during chondrocyte maturation was done.  These 
studies found that many of these genes have 1 or more Runx binding sites within 
2kb of their transcription start site, indicating that they are potential downstream 
Runx target genes.   
 Lastly, some preliminary experiments were done to characterize novel 
roles of Runx proteins in the chondrocyte.  Runx proteins have been shown to 
epigenetically regulate their target genes by remaining bound to them throughout 
x
mitosis, “poising” them for transcription upon exit from mitosis.  The hypothesis 
that Runx proteins also function by remaining bound to their target genes 
throughout mitosis in chondrocytes was tested.  It was demonstrated by 
immunofluorescense imaging of Runx proteins on metaphase chromosomes of 
ATDC5 cells, that Runx2 remains bound to chromosomes during mitosis.   
Cell proliferation and hypertrophy are both linked to increases in protein 
synthesis.  Runx factors, which regulate rates of global protein synthesis, are 
expressed in both proliferating and hypertrophic chondrocytes.  Thus, it was 
hypothesized that Runx proteins regulate rates of global protein synthesis during 
chondrocyte maturation.  These studies showed that the overexpression of Runx 
proteins in a chondrocyte cell line (ATDC5) did not affect protein synthesis rates 
or levels of protein synthesis machinery.  Additionally, Runx proteins did not 
affect proliferation rates in this chondrocyte cell line. 
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Osteoarthritis 
Osteoarthritis is a major public health issue in the United States, and it is 
estimated that as many as 26.9 million adults exhibited some type of clinical OA 
in 2005, with as many as 9.3 million adults having symptomatic knee OA. The 
prevalence of osteoarthritis is of significant financial burden both on the US 
healthcare system and on patients with the disease.  One study shows that OA 
increases insurer expenditures by as much as $149.4 billion/year, and out of 
pocket expenditures by $36.1 billion/year [1].  With the aging of the “Baby 
Boomer” generation, this cost is expected to increase with time.  In fact, the cost 
of total hip and knee replacements alone is expected to exceed $100 billion 
annually by the year 2030 [2]. Thus it is of public health interest to explore more 
cost-effective ways to detect, treat, and prevent this disease. This necessitates 
an understanding of the molecular processes that are involved with disease 
initiation and progression. 
This dissertation contributes to the molecular profiling of OA.  The 
characterization of the expression of Runx1 in normal articular and osteoarthritic 
cartilage, and the preliminary experiments on some novel functions of Runx 
proteins in cartilage, begin to explore the role of Runx proteins in cartilage and 
osteoarthritis.  By way of introduction, this is a general background on the current 
knowledge of gene expression during the disease process of osteoarthritis, as 
well as information about Runx family of transcription factors, and their role in the 
process of endochondral ossification, and permanent cartilage formation.  
3
Osteoarthritis: Risk Factors, Diagnosis, and Current Treatment Options 
There are many well-known risk factors for knee OA, including increased 
BMI, prior history of knee injury, certain occupations (such as farming, 
construction, and physical education instructors), increased bone mineral density 
(although increased bone mineral density is correlated with increased BMI, and 
so this may not be an independent risk factor), exercise, and previous 
menisectomy [3].  One of the most prevalent risk factors for development of OA 
is age, with an estimated 25% of asymptomatic patients over the age of 50 
predicted to develop knee pain within three years [4].  It is important to 
understand the molecular basis behind these risk factors.  It is well established 
that mechanical strain is a risk factor for development of OA, which explains why 
certain occupations and a history of knee injury are risk factors for its 
development.  For many years, it was thought that the obesity resulted in 
increased mechanical strain on knee joints, which accounted for the increased 
incidence of OA in overweight or obese people.  More recent literature shows 
that there is more than just increased mechanical strain that contributes to the 
development of OA in obesity [5-7].  Obesity is associated with an increase in 
systemic cytokines known as adipokines, which are released by adipose tissue.  
A chronic inflammatory state is associated with the development and progression 
of OA.  Specifically, IGF-1, TGF-B, IL-1, IL-6, TNF-a, prostaglandin E2, and NO 
have all been associated with OA [5].  IL-1B has been shown to increase MMPs 
while certain mutations in the IL-1 receptor IL1RN result in resistance to OA [6].  
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Leptin, another molecule that is released by adipocytes, induces expression of 
MMP1 and MMP3 in cartilage explants [7].  The correlation between the release 
of cytokines by adipose tissue, and the role of these inflammatory cytokines in 
OA can help explain why there is an increased incidence of OA in weight-bearing 
joints (knee, hip), as well as non weight-bearing joints (hands) in obese patients.   
There does, however, still seem to be an association between obesity and 
impaired biomechanics.  An increase in BMI is associated with an increase in the 
degree of knee malalignment [8], which is well-known to contribute to the 
pathogenesis of knee OA.  Other studies show that an increase in BMI is only 
associated with joint space narrowing in people who have moderate 
malallignments already [9] .  Additionally, Griffin et al. showed that obese mice 
have a higher incidence of OA, but that wheel running is protective [5].  This 
seems counter-intuitive given that wheel running results in a higher load on the 
knee joint.  One theory is that cyclic loading is protective in OA, with repetitive 
loading promoting an increase in antioxidants which helps battle cartilage 
damage by removing damaging free radicals from chondrocytes [5]. Taken 
together, these data show that there is a multi-factorial contribution of obesity to 
OA.   
The main risk factor for OA is age, and this is likely due to a composition 
of many of the above factors.  For example, it is common to find evidence of 
incidental meniscal damage on MRI in the elderly, which leads to joint space 
immobility, altered biomechanics, and osteoarthritis [10].  Aged cartilage has 
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lower levels of antioxidant enzymes than younger cartilage [11].  With cartilage 
strain promoting free radical production and lower levels of antioxidants, OA is 
more likely to develop.  As with obesity, cytokine signaling plays a role in the 
development of OA with age.  In fact, elderly patients with lower circulating levels 
of IL-1B had a lower incidence of hip OA, while elderly patients with lower levels 
of IL-6 and IL-1A had lower incidence of hand OA [12].    
 Currently, osteoarthritis is difficult to monitor and to treat.  Patients who 
present with joint pain and have joint space narrowing on X-ray are diagnosed 
with osteoarthritis.  By the time there is joint space narrowing on X-ray, there is 
no way to reverse the disease process.  In mice with surgically induced 
osteoarthritis, recombinant human PTH(1-34) was found to inhibit cartilage 
degeneration [13].  It is important to be able to monitor early disease progression 
in OA and to understand the molecular mechanisms that will inhibit and reverse 
cartilage damage.  The recent implementation of delayed gadolinium enhanced 
magnetic resonance imaging (dGEMRIC) may make it possible for to detect 
changes in cartilage matrix composition that take place in early stages of OA, 
prior to the detection of joint space narrowing by X-ray.  This imaging method is 
able to detect changes in cartilage matrix components in early OA, before there 
is cartilage destruction and joint space narrowing [14].  While this is promising, its 
widespread use is limited by cost and by the fact that even if OA changes were 
detected at an early stage, there are currently no treatment options in humans 
that are proven to halt the disease course.  
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Current treatment options for OA are extremely limited. The most common 
treatment options are acetaminophen or non-steroidal anti-inflammatory drugs 
(NSAIDs) to treat pain resulting from symptomatic OA [15].  The only treatment 
for advanced OA, accompanied by joint destruction, is a total joint replacement.  
Currently, 97% of total knee and 82% of total hip replacements are due to OA [2].  
It is clear that we must develop better treatment strategies than pain 
management and joint replacement, and there is a push for development of 
disease modifying osteoarthritis drugs (DMOADs).  Currently in clinical trials are 
items such as intra-articular stem cell injections, antioxidant therapy, IL1 receptor 
antagonists, and even BoTox therapy [16].  The most useful OA drugs would 
stop cartilage damage and even initiate cartilage repair.  An important first step in 
the development of these drugs is the understanding of the biological processes 
that occur during disease progression of osteoarthritis.   
 
 
Disease Mechanisms in Osteoarthritis 
 Although there is a genetic component to OA, there has been little 
progress identifying susceptibility loci that are linked to osteoarthritis.  Most loci 
that are identified in specific genome wide association studies (GWAS) are not 
consistent among different ethnic groups; or when sample size is increased, 
associations become insignificant [17].  There are, however, some loci that seem 
to be associated with an increased risk for developing OA, including secreated 
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frizzled-related protein 3 (SFRP3), a cluster of genes located on chromosome 
7q22, and the proteins growth/differentiation factor 5 (GDF5) and Iodothyronine-
deiodinase enzyme type 2 (DIO2) [17, 18].  While there are not many known 
susceptibility loci, there has been much research exploring the molecular 
mechanisms of osteoarthritis.   
 Pathological characteristics of OA include chondrocyte clustering, an 
increase in the production of specific extracellular matrix components (usually 
different from those produced in normal articular cartilage), and increased 
degradation of cartilage which leads to fibrillation of the cartilage surface [19].  At 
a molecular level, many changes in gene expression mimic those that occur 
during the transition to chondrocyte hypertrophy in growth plate chondrocytes.  
Genes such as SDC3 and ANXA5 [20], COL10A1 [21, 22], ACAN [22], MMP-13 
[23] and ADAMTS5 [24] are upregulated during the disease progression of 
osteoarthritis.  One study shows that increased hedgehog signaling leads to 
more severe OA [25], and another suggests that haploinsufficiency of Runx2 
leads to less severe OA in mice [26].  One study also suggests that abnormal 
maturation of chondrocytes in osteoarthritis may be due to loss of TGF-beta 
signaling after degradation of Smad2 and Smad3 [27].  Additionally, epigenetic 
modifications occur in OA such as DNA methylation, histone acetylation, and 
histone methylation [28]. There are also changes in micro RNAs present in 
cartilage that target many genes for protection of normal cartilage from 
inflammation and degradation [29].  
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 In addition to genetics, mechanical instability is a major cause of 
osteoarthritis.  Chondrocytes have receptors that can respond directly to 
mechanical signals, including stretch activated ion channels, CD44, Anchorin 2, 
and Integrin receptors [30].  In response to mechanical loading, cell-matrix 
interactions are disrupted, water content is increased, and tensile strength of the 
extracellular matrix is decreased [31].  In vitro studies have shown that shear 
stress increases Integrin receptor binding to specific ligands: Integrin B1 to 
fibronectin and Integrin B2 to vitronectin [32].  Additionally, chondrocytes from 
normal cartilage respond to pressure induced strain (PIS) [30] by membrane 
hyperpolarization, in contrast to the response of membrane depolarization by 
osteoarthritic chondrocytes [30].  These changes in response to pressure-
induced strain also lead to changes in gene expression, with normal 
chondrocytes increasing mRNA levels of aggrecan and decreasing levels of 
MMP-3 in response to PIS, and OA chondrocytes showing no change in these 
genes [30].   While there are differences in the ways that normal and diseased 
chondrocytes respond to PIS, it is known that PIS can cause an upregulation of 
genes that lead to the development of OA, such as ERK1/2 [33].
Understanding the molecular mechanisms during OA pathogenesis is an 
important step in identifying drugs that will both attenuate the severity of the 
disease and potentially reverse the cartilage damage that is a result of late stage 
OA.  In addition, understanding the different types of chondrocytes in articular 
and growth plate cartilage will help with the identification of a sub-population of 
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chondrocytes that has the potential to re-populate articular cartilage in response 
to damage caused by trauma or arthritis. 
Runx Family of Transcription Factors 
The Runx proteins are a family of transcription factors containing the conserved 
128 amino acid Runt homology domain [34].  All members of the Runx family, 
Runx1, Runx2, and Runx3, heterodimerize with Cbf? to enhance their DNA 
binding [34].  Runx proteins are able to both enhance and reduce transcription of 
their target genes [34]. Each member of the Runx family is a cell fate determining 
transcription factor and functional roles of Runx as master transcription factors 
have been well characterized.  Runx1 (CBFA2, AML1, PEBP2?B) is responsible 
for definitive hematopoiesis and mice lacking both alleles die before day E12.5 
due to hemorrhaging [35].  Runx2 (CBFA1, AML3, PEBP2?A) is required for 
osteoblast development and Runx2 -/- mice have a cartilaginous skeleton and 
die shortly after birth as a result of asphyxiation [36].  Runx2 interacts with a 
number of co-regulatory factors such as C/EBP, Smads, YAP, and Hes to 
regulate genes required for osteoblastogenesis (Lian 2003 [37]).  Runx3 (CBFA3, 
AML2, PEBP2?C) is involved in neurologic and gut development.  Different 
strains of Runx3 -/- mice show different phenotypes.  In an inbred background, 
Runx3 -/- mice do not survive longer than 10 days and it is hypothesized that 
they die of starvation as their blood sugar is low and their gastric mucosa is 
thickened as a result of increased proliferation and apoptosis [38].  In a Runx3 -/- 
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strain that was generated on a mixed background, mice live for several months 
but exhibit severe limb ataxia, consistent with the expression of Runx3 in the 
dorsal root ganglia [39].   
 In humans, all three Runx proteins are involved in disease.  
Haploinsufficiency of RUNX1 results in familial thrombocytopenia, characterized 
by a low platelet count [40]. Haploinsufficiency or genetic mutations of RUNX2 
result in cleidocranial dysplasia, a disease characterized by absence of clavicles, 
failure in closure of fontanelles, extra teeth, and short stature [41, 42].   
Additionally, all three Runx factors are involved in cancers.  Runx1 is one of the 
most common proteins involved in chromosomal translocations resulting in 
leukemias.  20% of acute lymphoblastic leukemias (ALL) and 13% of acute 
myelogenous leukemias (AML) contain a chromosomal translocation involving 
RUNX1 [43].  Commonly, the (8:21) translocation resulting in a fusion protein 
containing the DNA-binding domain of Runx1 fused to the entire ETO protein or 
the (12:21) translocation resulting in a fusion protein containing the N-terminus of 
Runx1 and TEL are found in the M2 subtype of AML and childhood pre-B cell 
ALL, respectively [44, 45].  Runx2 is commonly expressed at higher levels in 
osteosarcoma, prostate cancer, and breast cancer.  Runx2 is expressed 
abnormally in both breast and prostate cancer cell lines and its expression is 
increased in those cell lines derived from metastatic primary tumors and tumors 
that metastasize to bone [46].  Additionally, Runx2 activates many metastasis 
related genes and disruption of Runx2 function decreases the formation of 
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osteolytic lesions, showing that expression of Runx2 is important in the 
metastatic potential of primary breast and prostate cancers [47-49].  Runx3 has 
been implicated in a wide variety of cancers and is known to be a potent tumor 
suppressor in normal gastric epithelium [38]. One study shows that RUNX3 is 
hypermethylated in 64% of gastric cancers, 73% of hepatocellular carcinomas, 
62% of larynx cancers, and 46% of lung cancers [50].  Interestingly, Runx3 is 
also increased in pancreatic tumors, indicating that it can function as an 
oncogene when expressed aberrantly in normal cells, in addition to functioning 
as a tumor suppressor [51].  From the detrimental effects of Runx deletions in 
mice, and their altered expressions in many human cancers, it is clear that 
proper functioning and expression of Runx proteins is critical to maintain normal 
cellular function.  In this thesis, the roles of Runx factors, with a focus of Runx1 
and cartilage tissue, have been examined.  Further presentation of the Runx 
factors in the skeletal relationship to chondrogenesis and articular cartilage is 
found in each chapter exploring Runx function in chondrocytes.   
 
Endochondral Ossification and Mechanisms of Chondrocyte Hypertrophy 
During development, bones of the skeleton form by either intramembranous 
ossification (lateral clavicles and bones of the cranium) or endochondral 
ossification (medial clavicles, vertebrae, facial bones, ribs, and all long bones).  
During intramembranous ossification, mesenchymal progenitors differentiate 
directly into osteoblasts while during endochondral ossification, mesenchymal 
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cells condense and form a cartilage anlagen of the skeleton which is replaced by 
bone.  During endochondral ossification, mesenchymal progenitor cells condense 
to form the template for a long bone.  Cells at the center of the cartilage anlagen 
begin to differentiate into chondrocytes, expressing markers such as 
Collagen2a1, while cells located at distal portions of the anlagen proliferate at a 
slower rate and become resting zone chondrocytes.  Cells in the center then exit 
the cell cycle and increase greatly in size.  These hypertrophic chondrocytes are 
responsible for growth of the axial and apendicular skeleton. Hypertrophic 
chondrocytes begin to downregulate Col2a1 and upregulate Col10a1, alkaline 
phosphatase, osteopontin, and fibronectin.  Late stage hypertrophic 
chondrocytes express vascular endothelial growth factor (VEGF) and matrix 
degrading enzymes such as Mmp13, allowing for degradation of the cartilage 
matrix, and invasion of blood vessels, which carry osteoblasts to replace the 
cartilage skeleton with bone [52, 53]. 
 The process of chondrocyte maturation during endochondral ossification is 
tightly controlled by a number of transcription factors and regulatory pathways.  
The most important transcription factor for cartilage formation is Sox9, which is 
required for mesenchymal condensation to occur [54].  Additionally, Sox9 +/- 
mice mimic the phenotype of humans with Campomelic Dysplasia, characterized 
by underdevelopment of all skeletal elements [55].  Sox5 and Sox6 also play an 
important role in cartilage differentiation.  While Sox5 -/- and Sox6 -/- mice have 
only minor skeletal phenotypes, the Sox5/Sox6 double knockout shows marked 
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delays in chondrocyte proliferation and a decrease in the levels of many cartilage 
markers, including extracellular matrix components [56].  This indicates that while 
Sox5 and Sox6 may be functionally redundant, they are important components of 
chondrocyte differentiation.   
 The transition from proliferating to hypertrophic chondrocyte is complex 
and involves many signaling pathways.  The Indian Hedgehog (IHH)/Parathyroid 
Hormone Related Peptide (PTHrP) pathway is an important regulator of 
chondrocyte hypertrophy.  Ihh -/- mice show no deficiency in the initial cartilage 
condensation, however there is a vast decrease in the number of proliferating 
chondrocytes in these mice [57].  Additionally, conditional Ihh knockout mice, in 
which Ihh is deficient only in Col2 producing cells, show an increase in 
mineralization and a decrease in chondrocyte proliferation, providing evidence 
that IHH promotes chondrocyte proliferation and inhibits chondrocyte hypertrophy 
[58].  IHH, which is expressed in pre-hypertrophic chondrocytes, induces 
expression of PTHrP in chondrocytes of the resting zone.  PTHrP promotes 
chondrocyte proliferation, and also inhibits expression of IHH in pre-hypertrophic 
chondrocytes, providing a negative feedback loop to regulate proliferation of 
chondrocytes in the growth plate [59].    
 Another important signaling pathway during chondrocyte maturation is the 
Bone Morphogenic Protein (BMP) signaling pathway.  BMP binding to its 
receptor induces the phosphorylation of receptor Smads 1, 5, and 8.  These then 
dimerize with Smad4 and are transported to the nucleus where they can regulate 
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gene transcription [60]. BMP signaling increases the transition from resting to 
proliferating chondrocytes while inhibiting the transition to chondrocyte 
hypertrophy [61].  Studies also show that IHH increases BMP signaling in 
proliferating chondrocytes and in the perichondrium, indicating that these two 
pathways work together to promote chondrocyte proliferation [62].  TGF-beta, 
which is part of the same family as BMP, also contributes to the pathogenesis of 
osteoarthritis via Smad signaling. TGF-beta signaling via the ALK1 pathway 
leads to phosphorylation of Smads 1, 5, and 8 while TGF-beta signaling via the 
ALK5 pathway leads to phosphorylation of Smads 2 and 3 [63].  The balance 
between these two pathways is important in maintaining cartilage homeostasis 
and is disrupted in osteoarthritis [63].   
 Fibroblast growth factor (specifically FGF2 and FGFR3) signaling 
antagonizes the IHH and BMP signaling pathways by promoting chondrocyte 
hypertrophy and inhibiting chondrocyte proliferation, in part by increasing 
expression of the cell cycle inhibitor p21 [64, 65]. FGF signaling also negatively 
regulates IHH and BMP signaling, although the direct mechanisms remain 
unknown.  In vitro, FGF signaling decreases Smad phosphorylation, which leads 
to a decrease in BMP signaling; however, this phenomenon has not been seen in 
vivo [60].   
 In addition to the complex network of signaling pathways regulating 
chondrocyte maturation, an additional transcription factor is important for the 
transition from proliferation to hypertrophy.  Runx2, the essential transcription 
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factor for osteoblast differentiation, also regulates chondrocyte hypertrophy, as 
evidenced by the fact that Runx2 -/- mice only exhibit hypertrophic chondrocytes 
in distal skeletal elements [66].  Runx2/Runx3 double knockout mice, however, 
exhibit no hypertrophic chondrocytes, suggesting a functionally redundant role for 
these proteins during chondrocyte maturation [67].   Mice deficient for Runx1 in 
all non-hematopoietic lineages develop normal skeletons, with the exception that 
their sterna fail to mineralize [68].  However, a recent study shows that mice with 
a 50% reduction in Runx1 activity have growth plate irregularities and delayed 
fracture healing, as well as decreased expression of Runx2 and Runx3 in the 
growth plate [69].  This eludes to a possible function for Runx1 in cartilage, as it 
has been shown that Runx factors can regulate their own transcription, and the 
transcription of other Runx family members [70].  A summary of the growth plate, 
with its transcriptional regulators, phenotypic markers, and signaling pathways, 
can be seen in Figure 1.1.   
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Figure 1.1: Mechanisms of Control and Proteins Expressed during 
Chondrocyte Maturation 
A summary of mechanisms controlling each stage of chondrocyte maturation in 
the growth plate, along with proteins expressed at each stage of chondrogenesis.  
Red = resting chondrocytes, Purple = proliferating chondrocytes, Orange = pre-
hypertrophic chondrocytes, Blue = hypertrophic chondrocytes. 
 
Runx Proteins in Skeletal Development 
In addition to functioning as cell fate determining transcription factors, all three 
Runx proteins are found in cartilage during skeletal development.  Runx1, 2, and 
3 are present in the mesenchymal condensation and are downregulated for 
commitment to the chondrocyte lineage.   Runx1 is expressed in proliferating 
chondrocytes of the growth plate and in chondrocytes of permanent cartilage 
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structures, while Runx2 and Runx3 are present in pre-hypertrophic and 
hypertrophic chondrocytes. [36].   
 The most well studied Runx protein during cartilage development is 
Runx2.  Runx2 is important for chondrocyte hypertrophy and mice lacking 
functional Runx2 contain hypertrophic chondrocytes only in some skeletal 
elements (radius/ulna and tibia/fibula) [36].  Overexpression of Runx2 during 
development results in joint fusion and decreased length of long bones as a 
result of premature terminal chondrocyte hypertrophy [71]. Runx2 also controls 
many genes that are involved in chondrocyte hypertrophy, such as ColX, Ihh, 
and Mmp13 [72] [73] [74].  The expression of Runx2 and Runx3 in the same 
populations of growth plate chondrocytes suggests a possible functional 
redundancy of these proteins during development.  Interestingly, while Runx2 -/- 
mice still have hypertrophic chondrocytes in some skeletal elements, Runx2 -/-, 
Runx3 -/- mice have no ColX expressing hypertrophic chondrocytes [67].   
 Many recent studies have demonstrated a role for Runx1 during skeletal 
development.  Runx1 is expressed in the mesenchymal condensation, resting 
and proliferating zone chondrocytes, suture lines of the calvaria, periosteum, and 
hyaline cartilage [75].  Runx1 -/- mice, that have Runx1 restored in the 
hematopoietic and endothelial systems to bypass embryonic lethality exhibit a 
relatively normal skeleton; however they fail to develop a mineralized sternum 
and show some skeletal abnormalities [68].  In mesenchymal specific Runx1 
knockout mice, mesenchymal cells condense normally but have delayed 
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commitment to the chondrocyte lineage, while cartilage specific Runx1 knockout 
mice exhibit normal skeletal development [76].    This indicates that Runx1 is 
involved in, but not required for commitment to the chondrocyte lineage. 
 
Conclusions 
Many questions remain relating to the underspecified role of Runx1 during 
endochondral bone formation and in disorders associated with cartilage and 
bone disregulation.  Additionally, there is a need for a better understanding of the 
molecular basis of osteoarthritis.  This dissertation aims to characterize the 
expression of Runx1 in osteoarthritis, and begins to explore the possible role of 
Runx1 in healthy and diseased cartilage.  It also preliminarily explores some 
novel functions of Runx proteins including global protein synthesis control and 
epigenetic regulation of target genes.   
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CHAPTER II:  
Runx Expression in Normal and Osteoarthritic Cartilage 
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Abstract 
Runx1 is the only Runx factor that is expressed in the chondrocytes of 
permanent cartilage structures during development; however its role in normal 
joint functioning and cartilage disease is not known. To gain a basic 
understanding of Runx expression in non-diseased cartilage, IHC was done on 
full thickness immature bovine knee joints, showing Runx1 expression at greatest 
levels in superficial zone chondrocytes, and Runx2 expression at greatest levels 
in deep zone chondrocytes.  Runx1 protein and mRNA levels were quantified in 
response to static mechanical compression of bovine articular cartilage, and 
found to be upregulated under compression conditions.  To determine Runx1 
expression during OA disease progression, a mouse model of experimental OA, 
induced by surgical destabilization of the medial meniscus (DMM), was used.  To 
determine the expression of Runx1 in human osteoarthritis, the spared and 
diseased compartments in knees of OA patients were examined for Runx1 
expression by immunohistochemistry and Runx1 protein levels by Western blot 
analysis.  In human osteoarthritis, Runx1 expression is increased, and is 
visualized in chondrocyte clones in human disease. In some, but not all, mouse 
OA tissue sections, the Runx1-expressing chondrocytes appear to cluster at the 
peripheries of the OA lesions.  
 
 
 
21
 
Introduction 
During development of cartilage tissue in the process of endochondral 
ossification, all three Runx proteins are expressed in precursor cells in the 
condensing mesenchyme [77, 78].  Several studies have shown that in mouse 
embryonic fibroblasts, as well as in early mesenchymal cells, Runx2 protein must 
be downregulated for commitment to the chondrocyte lineage.  Experimental 
evidence suggests that the transcription factor Nkx3.2 [79] directly downregulates 
Runx2 [80, 81], with a concomitant upregulation of Sox9, a transcription factor 
critical for chondrogenic progression [54].  In committed chondrocytes, Runx1 
continues to be expressed only in proliferating chondrocytes [75], while Runx2 
and Runx3 are expressed in pre-hypertrophic and hypertrophic chondrocytes 
[71]. Runx2 in chondrocytes controls the transcription of hypertrophy-specific 
genes [67, 72, 74, 77], but the functions of Runx1 and Runx3 during 
chondrogenesis are less well understood.  
Deficiency of Runx3 causes chondrocyte maturation to be slightly delayed 
[82], and Runx3 may help compensate for haploinsufficiency of Runx2 [67]. 
During development, Runx1, a master regulator of the hematopoietic lineage [26, 
83], is the only Runx factor that is expressed in permanent cartilage structures 
[75, 78].  Mice deficient for Runx1 in non-hematopoietic lineages develop normal 
skeletons but their sterna fail to mineralize [68].  These findings suggest a role for 
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Runx1 in normal cartilage development.  However, the status of Runx1 during 
the progression of OA has not been examined.   
During osteoarthritis, many hypertrophic markers, such as MMP13, are 
upregulated leading to tissue degradation [84].  MMP’s are direct Runx targets 
[85, 86].  In the late stages of osteoarthritis, Runx2 is upregulated and is thought 
to play a role in the transcription of genes that lead to tissue destruction during 
late stages of the disease [25, 87].  Consistent with this hypothesis, 
haploinsufficiency of Runx2 leads to less aggressive OA in mice challenged with 
DMM surgery, indicating that Runx2 promotes OA progression [26].   The 
involvements of Runx1 and Runx3 in osteoarthritis have not been widely studied.  
As there is some evidence for redundancy of Runx2 and Runx3 function during 
chondrogenesis, the present studies aimed to explore the expression of Runx1 
during osteoarthritis.  
There are many cell culture models to facilitate the study of 
chondrogenesis; however, the study of osteoarthritis requires in vivo or ex vivo 
models.  To better understand protein regulation in response to mechanical 
stress, compression of bovine cartilage explants has been used extensively.  
Both static and cyclic compression can result in upregulation of inflammatory 
cytokines and a decrease in matrix synthesis [88].  The static compression model 
used in Dr. Fanning’s laboratory allows us to monitor for the upregulation of 
genes in response to mechanical compression within 6-24 hours.  This model 
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was chosen as it allows for the detection of changes that happen shortly after the 
induction of mechanical compression.   
There are also many animal models currently in use for the study of 
osteoarthritis.  Mice and rats are especially advantageous due to their low cost 
and ease of genetic manipulation to study particular genes involved in OA 
pathogenesis. The disadvantages are the thin cartilage and increased calcified 
cartilage in the mouse, as well as the pain response in osteoarthritic rats [89].    
There are very few animal models of naturally occurring osteoarthritis.  There are 
a number of experimental models targeted at inducing mechanical and structural 
joint instability.  Inducing structural instability involves direct damage to the 
cartilage (e.g. surgical trauma, freezing, ionizing radiation, etc.) to look for a 
direct response to cartilage damage, while mechanical instability involves 
disruption of the knee-stabilizing ligaments (e.g. patella dislocation, ACL 
transection, menisectomy, etc.), resulting in altered loads on knee cartilage [90].  
A mouse model using destabilization of the medial meniscus (DMM) to induce 
OA was chosen for these studies.  This surgery involves transecting the medial 
meniscotibial ligament, leading to knee joint instability that produces a focal 
lesion on the medical side of the knee, while mostly sparing the lateral side, a 
pattern that mimics the vast majority of human osteoarthritis [91].  This model is 
also advantageous as the changes occur rapidly, with apoptosis occurring by 2 
weeks post-surgery Changes in gene expression were detected as early as 8 
days post-surgery, making this an ideal model to study gene expression changes 
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during osteoarthritis progression.  The goal of this study was to identify the 
expression pattern of Runx1 in mouse, bovine, and human normal and 
osteoarthritic cartilage, and to determine the response of Runx1 expression to 
cartilage stress conditions.   
 
Materials and Methods 
Bovine Studies 
A. Isolation of Articular Cartilage Zones 
Superficial (SZ), middle (MZ), and deep zone (DZ) chondrocytes were harvested 
from the femoropatellar groove of 1-week-old male calves as previously 
described [92].   Briefly, the SZ cartilage was harvested from the 100 µm of 
tissue at the articular surface using a scalpel (final volume is approx. 5% by 
weight), while the MZ and DZ tissues were harvested from the next 60% and 
35% of tissue, respectively (by wet weight) moving toward the sub-chondral 
bone.  
B. Compression Experiments 
Full thickness cartilage plugs were isolated from a 2-10 day old bovine knee joint 
using a hollow drill-bit measuring 1cm in diameter. The plugs were sliced into 
1mm thick sections and a 3mm biopsy punch was used to obtain discs with final 
measurements of 3mm in diameter x 1mm.  One bovine knee joint generates 
more than 36 plugs for experimental use (n=12/group). 12 cartilage discs were 
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cultured in either one well of a 6-well plate (free swelling control) or under 
conditions of 25% or 50% compression for 3 days in Dulbecco’s Modified Eagle 
Medium (DMEM) supplemented with insulin-transferrin-sodium selenite 
(ITS)(Sigma) and Pen/Strep (Gibco).  For compression experiments, discs were 
cultured in compression apparatus that holds 12 discs in individual compartments 
under conditions of constant compression.  In each set, medium was changed 
the first day after harvest, and every three days thereafter. Repetitive 
experiments were performed with 36 discs from 2 calves.  Statistics were 
performed in 24 samples comparing 0%, 25%, and 50% compression groups.  
 
Mouse Osteoarthritis Model 
Osteoarthritis was surgically induced in the right leg of 10-week old male 129 
S6/SvEv mice by destabilization of the medial meniscus (DMM) as previously 
described [91].    Briefly, mice were anesthetized using inhaled Isofluorane 
(HaloCarbon Corp, NJ) titrated to the appropriate effect.  Unilateral joint instability 
was induced by aseptically preparing the knee with iodine and alcohol, opening 
the joint capsule medial to the patellar tendon, and transecting the anterior 
attachment of the medial meniscotibial ligament.  The joint capsule was closed 
using a running 7-0 Vicryl (Ethicon) suture and the skin incision was closed using 
an interrupted 7-0 Vicryl suture.  In sham-operated animals, the skin and joint 
capsule were surgically opened but the medial meniscotibial ligament was left 
intact.  Two mice were harvested at each time point for both DMM animals and 
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one mouse was harvested at each time point for Sham-operated animals.  
Immunofluorescense and immunohistochemical analysis were repeated at least 
twice for each study.   
 
Mice 
129S6/SvEv mice were obtained from Taconic Farms (Germantown, NY), 
housed in cages with a maximum of five animals per cage, and allowed free 
access to food and water.  They were cared for in accordance with the National 
Institutes of Health and American Association of Laboratory Animal Care 
regulations, in addition to the University of Massachusetts Medical School’s 
Institutional Animal Care and Use Committee protocols. 
 
Samples from Human Osteoarthritic Patients 
Knee joints were obtained from osteoarthritic patients with varus malalignments 
undergoing total knee replacements at the time of surgery, in accordance with 
the institution’s policy on discarded samples. For protein data, patient samples, 
gender, and age are presented in Table 2.1. For immunohistochemistry and 
immunofluorescense, samples were obtained from 6 patients (2 male and 4 
female) ranging in age from 46 to 79, with a mean age of 67 and a median age of 
68.  At the time of surgery, the tibial plateau and medial and lateral condyles of 
the femur were removed and placed into phosphate buffered saline.  Full 
thickness articular cartilage samples (from surface to bone) were removed from 
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the tibial plateau and from both the medial and lateral condyles of the femur. 
Each of these tissues was divided into serial samples to be used for 
immunohistochemistry and western blotting.   
 
Immunohistochemistry and Immunofluorescense 
Human cartilage samples were isolated as described above.  Intact right knees of 
mice were removed by performing a hemi-pelvectomy. Samples from human and 
mouse were fixed in freshly prepared 4% paraformaldehyde in cacodylate buffer 
for 24 hours, with a change in buffer after 16 hours, dehydrated through a series 
of graded ethanols to citrusol (Fisher Scientific) and then embedded in paraffin 
for sectioning at a thickness of 6µm. 
Safranin O staining was performed as previously described [93].  For 
immunohistochemistry (IHC) to detect Runx1 and PCNA, paraffin sections were 
rehydrated through a series of graded alcohols to phosphate buffered saline.   
Blocking of endogenous peroxidase was carried out using 3% hydrogen peroxide 
in methanol.  Antigen retrieval was performed using citrate buffer at high 
temperature in a pressure-cooking apparatus, the 2100 Retriever apparatus, 
according to the manufacturer’s specifications (Pick Cell Laboratories). Non-
specific sites for antibody binding were blocked by 5% BSA in PBS for 1 hour, 
sections were then incubated in primary antibody overnight.  The next day, 
sections were washed three times in wash buffer (0.1% BSA, 0.2% gelatin, 
0.05% saponin in PBS), then incubated in secondary antibody for 2 hours, and 
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washed three times in wash buffer.  Staining was visualized using the DAB 
detection system (Dako). 
Immunofluorescense [94] studies were used to detect Runx1 in bovine, 
human, and mouse cartilage sections.  Paraffin sections were rehydrated through 
a series of graded alcohols to phosphate buffered saline.  To reduce 
autofluorescense, sections were washed 3 times, for 10 minutes each, in 
1mg/mL sodium borohydride, and washed 3 times in 1% Tween in phosphate 
buffered saline. Antigen retrieval was performed using citrate buffer at high 
temperature in a pressure-cooking apparatus, the 2100 Retriever apparatus, 
according to the manufacturer’s specifications (Pick Cell Laboratories).  Proteins 
were blocked for non-specific dye binding using the Image-iT FX Image 
Enhancer Solution (Invitrogen) according to the manufacturer’s specification, 
blocked for non-specific antibody binding in 6% BSA in PBS for 1 hour, and then 
incubated in primary antibody overnight.  Sections were washed then 3 times in 
1% Tween in phosphate buffered saline, incubated in secondary antibody for 2 
hours, and nuclei were counter-stained with DAPI (0.1ug/mL) to visualize cell 
nuclei.  Sections were visualized on a Zeiss Axioplan fluorescence microscope 
using MetaMorph imaging software.   
The Runx1 antibody used for bovine, mouse, and human sections for both IF and 
IHC was AML-1, raised in rabbit (1:200 Cat# 4334, Cell Signaling Technologies). 
The secondary antibody used for immunohistochemistry was goat anti-rabbit, 
HRP conjugate (1:800 Cat# SC-2004, Santa Cruz).  The secondary antibody 
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used for immunofluorescense was avidin, Alexa Flour 488 Conjugate  (1:800 
Cat# A21370, Invitrogen). 
 
 
Western Blot Analysis 
Cartilage samples from human and bovine knee joints to be used for western 
blotting were flash-frozen in liquid nitrogen, pulverized with a Bessman tissue 
pulverizer (Fischer Scientific), chilled in liquid nitrogen, and put into Lysis Buffer 
(50mM Tris pH 8.8, 150mM NaCl, 1% NP-40, 1% SDS, 10% glycerol, 0.5% 
deoxycholic acid, 0.6M DTT, 100mM NaF, 2mM Na3VO4, 1X Complete Mini 
Protease Inhibitor (Roche), 25µM MG132) for protein extraction. For bovine 
experiments, 12 cartilage discs were harvested from the same compression 
chamber and pooled together for protein isolation.  Cartilage from human 
patients was obtained at the time of surgery.  Data on western blots from human 
samples were an average from 5 patients.   Proteins were separated by SDS-
PAGE, transferred to a nitrocellulose membrane, and probed for the presence of 
Runx1.  Antibodies used were AML-1, rabbit polyclonal (1:1000, Cat# 4334, Cell 
Signaling Technologies), Pan-Runx antibody 2B5 mouse monoclonal, a 
generous gift from Dr. Kosei Ito (1:1000, Kyoto University Hospital, Kyoto, 
Japan), and GAPDH, goat polyclonal (1:5000, Cat# SC-31915 Santa Cruz).  
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qPCR 
Bovine cartilage samples (n=12 plugs/sample) to be used for RNA isolation were 
flash-frozen in liquid nitrogen, and pulverized as above.  Each sample was 
homogenized in 1mL of Trizol using a Polytron PT1200 homogenizer for 20 
seconds on level 1.  RNA isolation was carried out by phenol/chloroform 
extraction followed by ethanol precipitation.  DNA contamination was removed 
using the DNase-free RNA kit (Zymo) according to the manufacturer’s 
specifications.  Nucleic acid quantification was carried out using a Nano-drop 
spectrophotometer, and RNA purity was assessed using the 260/280 ratio.  One 
µg of RNA was reverse transcribed into cDNA with the First Strand cDNA 
synthesis kit (Invitrogen) using random hexamers according to the 
manufacturer’s protocol.  RT-PCR was preformed on a 7500 fast RT-PCR 
machine (Applied Biosystems).  Samples were run in duplicate using 20ng of 
cDNA, 5µM forward and reverse primer, and SybrGreen Master Mix (Bio Rad) in 
a 20 µL reaction.  Values were normalized to B-actin.  Primers used were as 
follows: Runx1 Forward 5’ AACCCTCAGCCTCAGAGTCA 3’; 
Runx1 Reverse 5’ GCGATGGATCCCAGGTACT 3’; B-actin Forward 
5’CTGCGGCATTCACGAAACTA 3’; B-actin Reverse: 5’ 
ACCGTGTTGGCGTAGAGGTC 3’. 
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Results 
Runx1 and Runx 2 are Expressed in Immature Bovine Articular Cartilage 
To determine baseline Runx levels in healthy cartilage, full thickness cartilage 
sections were obtained from immature bovine knee joints.  Immunohistochemical 
analysis demonstrated that, at this stage of cartilage development, both Runx1 
and Runx2 were expressed throughout the cartilage (Figure 2.1).  However, 
Runx1 immunohistochemical staining was highest in the most superficial zone 
chondrocytes (Figure 2.1 A-E), while the staining for Runx2 was stronger in deep 
zone chondrocytes (Figure 2.1 D-F).  Runx1 expression was analyzed in 
chondrocytes isolated from the superficial, middle, and deep zones of bovine 
articular cartilage (thickness shown in figure 2.2A, lower).  Quantitative RT-PCR 
analysis shows that expression levels of Runx1 are highest in the superficial 
zone and diminish through the deep zone (Figure 2.2A, upper), with levels of 
Runx1 being significantly different between the superficial and deep zones 
(p<0.05).  
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Figure 2.1:  Runx1 and Runx2 Expression in Immature Bovine Knee 
Cartilage.   
Immunohistochemistry of Runx1 (A,B,C) and Runx2 (D,E,F) in the superficial 
(A,D), middle (B,E), and deep (C,F) zones of immature bovine articular cartilage 
shows Runx1 expression  most strongly in the superficial zone (denoted by the 
arrow) and Runx2 expression most strongly in the deep zone.  
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Runx1 is Upregulated in Response to Mechanical Compression  
Since OA is a disease that results from chronic overloading of articular 
cartilage, it is of interest to determine if Runx1 responds directly to mechanical 
compression. Bovine cartilage plugs (see Methods) that underwent 3 days of 
compression began to show loss of extracellular matrix as evidenced by loss of 
Safranin-O staining, indicating that compression of these plugs mimics the 
disease process of OA (data not shown). Quantitative PCR analysis shows that 
Runx1 mRNA levels are upregulated in response to graded degrees of tissue 
strain after as little as 6 hours of mechanical compression.  Runx1 levels 
continue to increase through 16 hours of compression (Figure 2.2B). Western 
blot analysis of protein samples shows that Runx1 protein is upregulated in 
cartilage plugs after undergoing three days of either 25% or 50% strain when 
compared to control plugs that remained uncompressed during culture (Figure  
2.2C, upper panel, n=3). The lower panel shows a corresponding representative 
immunoblot that reveals a clear Runx1 doublet band, both of which are included 
in the densitometry measurements for figure 2D. As it is a Runx1 specific 
antibody that is detecting this doublet, it is possible that these doublet bands 
represent different Runx1 isoforms. However, the identity of each individual band 
was not determined.  Thus, the elevated Runx1 that occurs in normal bovine 
cartilage in response to compression suggests that the increased Runx1 
observed in human OA samples is a consequence of mechanical strain on the 
diseased joints. 
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Figure 2.2: Runx1 is Upregulated in Bovine Cartilage in Response to 
Mechanical Compression.   
(A) Upper: Quantitative RT-PCR analysis of Runx1 mRNA in the 
superficial, middle and deep zones of normal bovine articular cartilage were 
compared using Tukey’s test, *=p<0.05.  Middle: Immunohistochemistry showing 
the zonal distribution of Runx1 in bovine articular cartilage (100x).  The arrow 
indicates Runx1 in the superficial zone. Lower: Safranin O staining showing 
isolation of cartilage zones.  (B) Quantitative Real Time PCR of Runx1 mRNA in 
samples undergoing 0%, 25%, or 50% compression for 6 or 16 hours (n=12 
pooled samples per group; duplicate assay of samples). Data from 25% or 50% 
compression was compared to 0% compression using Tukey’s test, *=p< 0.05. 
(C) Upper: Quantitation of immunoblot analysis shows a significant increase of 
Runx1 protein levels in response to 25% or 50% compression when compared to 
uncompressed samples (Tukey’s test, *=p<0.05).  Lower:  Representative 
immunoblots of Runx1 protein and GAPDH (loading control) in compressed 
cartilage samples. 
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Runx1 is Expressed in a Subpopulation of Chondrocytes in a Mouse Model of 
OA   
To better characterize the changes in Runx1 gene expression in osteoarthritis, as 
related to compression of the diseased tissue, OA was generated in a mouse 
model by destabilization of the medial meniscus (Glasson, 2007 [91]).  This 
surgery creates a focal osteoarthritic lesion on the medial side of the joint, while 
sparing the lateral side of the joint, allowing for examination of Runx1 during the 
progressive degeneration of articular cartilage over a 3-week period.  In sham-
operated animals, no arthritic lesions were observed and Runx1 was detected in 
the population of chondrocytes that are present near the joint surface (Figure 2.3 
sham).  In the damaged cartilage tissue, Runx1 immunostaining began to drop 
out of the area of the lesion at day 4.  However, by day 8, Runx1 was observed 
in chondrocyte clusters located at the periphery of the OA lesions.  These 
clusters remained present throughout the time course (Figure 2.3). The presence 
of Runx1 in the normal surface layer of articular cartilage suggests a role in 
maintaining the surface integrity of normal articular cartilage.  Runx1 is depleted 
in OA lesions, but induced in chondrocyte clusters at lesion peripheries.   
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Figure 2.3:  Runx1 is Expressed at the Periphery of OA Lesions in a Mouse 
Model of OA.   
DIC (differential interference contrast) and immunofluorescense showing the 
progression of Runx1 development around the sites of an osteoarthritic lesion 
(40x).   Images show the medial side of a mouse knee joint, with the femoral 
cartilage at the top, and the tibial cartilage at the bottom of the picture. Note the 
droupout of Runx1 in the area of the lesion, followed by the presence of Runx1 
[95] in clusters of chondrocytes at the lesion periphery by day 16 (indicated by 
arrows). Nuclei are stained using DAPI (blue).  
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Runx1 is Upregulated in Human Osteoarthritis.   
In patients with varus knee malalignments, osteoarthritis is more severe on the 
medial side (OA) of the knee than on the lateral side (spared), as can be seen in 
Figure 2.4A by the loss of Safranin O staining, severe fibrillation, and 
chondrocyte cloning in the medial compartment of this malalligned knee.  Also 
observed are the typical clustered chondrocytes, or “clones”, in the affected OA 
area (arrows in Figure 2.4A, right panel).  Since Runx1 expression predominates 
in articular cartilage, and is differentially expressed during mouse OA, it was 
hypothesized that its expression would be modified in human OA tissue as well. 
Immunoblot analysis of cartilage from both compartments using a Runx1 specific 
antibody shows an upregulation of Runx1 protein levels in n=5 knees.  The 
medial tibial and femoral compartment samples are increased 2-fold and 2.5-fold, 
when compared to lateral tibial and femoral compartment samples, respectively 
(p<0.05, Table 2.1 and Figure 2.4B, left). Two representative immunoblots from 
two different patients are shown for Runx and GAPDH protein in contiguous 
slices of each compartment using Runx1 antibodies from two sources (see 
methods, figure 2.4B right). Immunohistochemical analysis of additional tissue 
samples from the same patient knees indicates the cellular localization of Runx1 
in articular cartilage. Runx1 protein is detected in normal chondrocytes of the 
spared compartment (figure 2.4C, left).  Chondrocytes expressing Runx1 
observed in the spared compartment are located mainly in the superficial zone. 
There are some clusters of chondrocytes in the spared compartment, indicating 
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that there is evidence of disease even on the spared side of an OA joint.  These 
clusters, characteristic of fibrillated OA cartilage, are enriched in the medial 
diseased compartment of the joint and show the presence of Runx1 (Figure 
2.4C, right). Taken together, these data indicate that Runx1 is upregulated in 
response to the cartilage damage in human osteoarthritis. 
 
 
    Lateral Femur   Medial Femur   Tibia 
Age Gender 
Anterior 
Femur 
Posterior 
Femur 
Combined 
LF  
Anterior 
Femur 
Posterior 
Femur 
Combined 
MF  
Lateral 
Tibia 
Medial 
Tibia 
            
52 F   0.17 (0.1)    
1.37 
(0.31)  NC NC 
            
81 F 
0.92 
(0.25) 
0.11 
(0.06) 
0.14 
(0.05)  
0.50 
(0.11) 
0.24 
(0.04) 
0.22 
(0.08)  
0.52 
(0.05) 
0.74 
(0.28) 
            
52 F 
0.05 
(0.01) 
1.18 
(0.2) 
1.71 
(0.42)  
1.35 
(0.48) 
1.28 
(0.11) 
1.60 
(0.65)  
0.55 
(0.09) 
0.95 
(0.09) 
            
66 F   
0.68 
(0.09)    
1.24 
(0.44)  NC NC 
            
64 F 
0.01 
(0.08) 
0.55 
(0.25) 
0.25 
(0.08)   
1.18 
(0.15) 
1.02 
(0.13) 
1.01 
(0.51)   
0.44 
(0.08) 
0.63 
(0.06) 
 
Table 2.1: Summary of Runx1 Experimental and Patient Data from Human 
OA Knees  
NC = Not collected. In some combined samples, anterior and posterior tissues 
were not separated.  Densitometry measurements of Runx1 protein levels by 
Western blot are expressed as mean (+/-­‐ SEM) 
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Figure 2.4:  Runx1 is Upregulated in Human Osteoarthritis.   
(A) X-ray from a patient with a malalligned right knee showing compression in the 
medial compartment (*) of the knee and a normal joint space in the lateral 
compartment (#) (Sample K1 in Table 1).  Safranin O staining shows loss of 
extracellular matrix on the medial side of the joint versus normal extracellular 
matrix on the lateral side.  Arrows indicate “clones”. (B) Graph shows mean +/- 
SEM quantitation of western blots stained for Runx1 of cartilage tissue from 5 
patients.  Data from the medial and lateral compartments were compared using 
Tukey’s test, *=p<0.05.  (C) Representative western blots from human knees 
using a pan-Runx antibody (upper) and a Runx1-specific antibody show 
increased Runx1 on the medial (OA) side of the joint when compared to the 
lateral side.  Different lanes are sections of cartilage from the medial and lateral 
sides from one human knee.  (D) Immunohistochemical staining using a Runx1 
specific antibody on the lateral (spared) and medial (OA) compartments. 
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Conclusion 
In articular cartilage, Runx1 is expressed at the highest levels in the superficial 
zone, the 1-2 cell layer closest to the joint surface of articular cartilage, while 
immunohistochemical staining for Runx2 is strongest in deep zone chondrocytes.  
As previously mentioned, superficial and deep zone chondrocytes exhibit 
different properties.  Superficial zone chondrocytes have higher proliferation 
rates, a smaller size, and higher Sox9 expression than their deep zone 
counterparts [92].  The Runx expression patterns also reflect what is seen in the 
growth plate, with Runx1 expressed at higher levels in the proliferating 
chondrocytes, which are smaller in size and express higher levels of Sox9 than 
hypertrophic chondrocytes, which have high Runx2 expression.   
Runx1 expression is upregulated in osteoarthritic cartilage in humans, and 
in a mouse model of OA.  In vitro compression of bovine cartilage explants 
demonstrates that this upregulation could be a direct response to the cartilage 
compression that occurs in osteoarthritic joints.  In human OA cartilage, Runx1 is 
localized to chondrocyte “clones”, while in mouse OA cartilage, Runx1 
expressing chondrocytes can be found in clusters at the periphery of OA lesions.  
The expression pattern in the superficial zone chondrocytes, and at the border of 
mouse OA lesions suggests a possible protective role of Runx1, possibly 
establishing a barrier of healthy cartilage around the diseased cartilage.   
41
 
 
 
CHAPTER III: 
Runx1 is expressed with Markers of Mesenchymal Progenitor Cells and 
Proliferation in Osteoarthritic Cartilage 
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Abstract 
Runx1 functions as a critical hematopoietic transcription factor for normal 
cellular differentiation of hematopoietic lineage cells.  Runx1 is expressed 
in periosteum, perichondrium, and early osteo-chondral progenitor cells 
[77].  However, the tissue related functions of Runx1 in articular cartilage 
are poorly understood.  The most superficial layer of articular chondrocytes 
has been shown to express markers for mesenchymal progenitor cells 
[96].  Additionally, in growth plate chondrocytes, Runx1 is found in 
proliferating cells.  To gain insight into the potential role of Runx1 in 
articular cartilage, a series of immunofluorescense experiments was 
carried out.  The hypothesis was tested that since Runx1 is found in 
superficial zone chondrocytes, it may be co-expressed with markers of 
mesenchymal progenitor cells in both normal and OA cartilage.  It was also 
hypothesized that the clonal populations containing Runx1 positive cells 
may be a result of proliferation and that Runx1 may function to support the 
activity of these populations.  Runx1 is expressed in cells that also express 
VCAM-1, which is a marker for mesenchymal progenitor cells, in both 
normal and osteoarthritic cartilage.  Further, in osteoarthritic cartilage, 
Runx1 is expressed with the markers for proliferation Ki-67 or PCNA.  
Overexpression of Runx1 in ATDC5 cells, which are described in more 
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detail in Chapter IV did not result in increased proliferation in these cells.  
Finally, a candidate gene approach was used to identify Runx binding sites 
in promoters of genes that are differentially expressed during 
chondrogenesis.  Based on this study, candidate genes were chosen for 
analysis on the basis of their functions during OA; however the expression 
levels of these genes were not significantly changed by overexpression of 
Runx1.  
Introduction 
The superficial zone of articular cartilage, which shows expression of 
Runx1 (Figure 2.1), is different from the middle and deep zones in both 
morphology with respect to organization of collagen fibrils, and gene expression 
[97]. When cultured, cells of the superficial zone have higher rates of proliferation 
than cells of the deep and middle zones [92].  In addition, these superficial zone 
cells have been shown to express markers of mesenchymal progenitor cells such 
as Notch-1, Endoglin (CD105), ALCAM (CD166), and VCAM-1 (CD106) [97-99].  
Interestingly, the clones of osteoarthritic cartilage have properties similar to the 
cells of the superficial zone.  Certain osteoarthritic “clones” have been shown to 
express markers for mesenchymal progenitor cells, including VCAM-1[96, 100, 
101]; and many studies show that these clones represent a proliferative cell 
population [20, 102].  
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The expression of Runx1 in the most superficial layer of articular cartilage 
is not surprising.  Runx1 is also expressed in the epithelium of skin, nails, oral 
mucosa, hair follicles, and at the base of colonic crypts [103].  These populations 
of cells, like the most superficial layer of articular cartilage, contain progenitor 
cells [93, 103]. The role of Runx1 in progenitor cells has been studied in a wide 
variety of cell types, and is related to both proliferation and differentiation.  A 
short isoform of Runx1, AML1a, is responsible for expansion of hematopoetic 
progenitor cells [104].  Overexpression of Runx1 promotes proliferation by 
stimulating the G1/S cell cycle transition [105, 106].  In hair follicle stem cells, 
downregulation of Runx1 causes decreased proliferation by upregulation of p21 
[107].  Additionally, Runx1 overexpression can overcome contact-dependent 
inhibition of proliferation in p53-/-, but not normal MEFs [108].  In contrast Runx1 
overexpression causes a decrease in proliferation in microglial cells, showing 
that it can have pro- or anti-proliferative properties depending on the cell type 
[95].  In addition to being associated with proliferation and progenitor cells, 
Runx1 is upregulated in response to injury in a number of cell types.  For 
example, Runx1 is upregulated in microglia in response to nerve injury [95], and 
injury to the inter-follicular epidermis of the hair follicle results in an increase in 
both proliferation and Runx1 expression [103].  Because of the proliferative and 
progenitor cell properties of the superficial zone cells, and because of the 
association of Runx1 with proliferation and progenitor cell markers, the aim of 
this study was to further characterize the Runx1 positive chondrocytes in normal 
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articular and osteoarthritic cartilage, specifically characterizing the progenitor cell 
properties and proliferation potential of these cells.  
 
Materials and Methods 
Samples from Human Osteoarthritic Patients 
Knee joints were obtained from osteoarthritic patients with varus malalignments 
undergoing total knee replacements at the time of surgery, in accordance with 
the institution’s policy on discarded samples, as described in Chapter II.  Full 
thickness articular cartilage samples (from surface to bone) were removed from 
the tibial plateau and from both the medial and lateral condyles of the femur. 
Each of these tissues was divided into serial samples to be used for 
immunohistochemistry and western blotting.   
 
Mouse Osteoarthritis Model 
Osteoarthritis was surgically induced in the right leg of 10-week old male 129 
S6/SvEv mice by destabilization of the medial meniscus (DMM) as described in 
Chapter II.  Two mice were harvested at each time point for both DMM animals 
and one mouse was harvested at each time point for Sham-operated animals.  
Immunofluorescense and immunohistochemical analysis were repeated at least 
twice for each study.   
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Mice 
129S6/SvEv mice were obtained from Taconic Farms (Germantown, NY), 
housed in cages with a maximum of five animals per cage, and allowed free 
access to food and water.  They were cared for in accordance with the National 
Institutes of Health and American Association of Laboratory Animal Care 
regulations, in addition to the University of Massachusetts Medical School’s 
Institutional Animal Care and Use Committee protocols. 
 
Immunohistochemistry and Immunofluorescense 
Human cartilage samples were isolated as described above.  Intact right knees of 
mice were removed by performing a hemi-pelvectomy. Samples from human and 
mouse were fixed in freshly prepared 4% paraformaldehyde in cacodylate buffer 
for 24 hours, with a change in buffer after 16 hours, dehydrated through a series 
of graded ethanols to citrusol (Fisher Scientific) and then embedded in paraffin 
for sectioning at a thickness of 6µm. 
Immunofluorescense [94] studies were used to detect Runx1, VCAM-1, 
and Ki-67.  Paraffin sections were rehydrated through a series of graded alcohols 
to phosphate buffered saline.  To reduce autofluorescense, sections were 
washed 3 times, for 10 minutes each, in 1mg/mL sodium borohydride, and 
washed 3 times in 1% Tween in phosphate buffered saline. Antigen retrieval was 
done in Antigen Retrieval buffer (Dako) in a 2100 Retriever (Pick Cell 
Laboratories).  Proteins were blocked for non-specific dye binding using the 
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Image-iT FX Image Enhancer Solution (Invitrogen) according to the 
manufacturer’s specification, blocked for non-specific antibody binding in 6% 
BSA in PBS for 1 hour, and then incubated in primary antibody overnight.  
Sections were washed then 3 times in 1% Tween in phosphate buffered saline, 
and incubated in secondary antibody for 2 hours, and stained with DAPI 
(0.1ug/mL) to visualize cell nuclei.  Sections were visualized on a Zeiss Axioplan 
fluorescence microscope.   
The Runx1 antibody used for mouse and human sections for both IF and IHC 
was AML-1, rabbit polyclonal (1:200, Cat# 4334, Cell Signaling Technologies). 
For IF, VCAM-1 (1:200, Cat# 1504, Santa Cruz), and Ki-67 (1:200, Cat# ab8191, 
Abcam) were used and for IHC, PCNA (1:200, Cat# ab29, Abcam).  
Secondary antibodies used for immunohistochemistry were goat anti-mouse, 
HRP conjugate (Cat# SC-2005, Santa Cruz), and goat anti-rabbit, HRP 
conjugate (Cat# SC-2004, Santa Cruz).  Secondary antibodies used for 
immunofluorescense were Alexa Fluor 488 donkey anti-rabbit (Cat# A21206, 
Invitrogen), Alexa Fluor 594 donkey anti-goat (Cat# A11058, Invitrogen), and 
Alexa Fluor 594 donkey anti-mouse (Cat# A21203, Invitrogen).  All secondary 
antibodies were used at a dilution of 1:800. 
 
Cell Culture Conditions 
ATDC5 cells were maintained in DMEM/F12 Medium supplemented with 2mM L-
glutamine, 100 U/mL penicillin, 100 µg/mL streptomycin, 10% FBS, 10µg/mL 
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transferrin, and 3x10-8M sodium selenite, and passaged at 80% confluence to 
maintain cells in a pre-chondrocyte state until they were used for transfection 
experiments.  Cells were cultured at 37oC in the presence of 5% CO2. 
 
 
Runx1 Overexpression 
For Runx overexpression, vectors containing full-length mouse Runx1 in a 
pcDNA backbone was generated.  For transformation experiments, ATDC5 cells 
were plated at 100,000 cells/well in a 6-well plate or 666,666 cells/plate in a 
100mm plate.  Cells were transfected with either an empty vector or a vector 
containing Runx1 using X-treme gene transfection reagent (Roche, Mannheim, 
Germany) according to the manufacturer’s protocol, using 1µg of plasmid and 
3µL of transfection reagent.  Cells were grown up to 48h post-transfection and 
cells were harvested at the time points specified below.   
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Results 
Runx1 Co-localizes with Markers of Mesenchymal Progenitor Cells in Normal 
and Osteoarthritic Cartilage   
To determine if Runx1 is expressed in the same populations of chondrocytes that 
express markers of mesenchymal progenitor cells, knee joints were harvested 
from mice undergoing DMM surgery as well as control mice at the time points 
listed above, and Runx1 and the MPC marker VCAM-1 were detected by IF.  At 
the surface of normal articular cartilage, Runx1 and VCAM-1 are found in the 
same population of chondrocytes (Figure 3.1A right).  Interestingly, Runx1 and 
VCAM-1 are also found in the same characteristic clustered cells at the periphery 
of osteoarthritic lesions (Figure 3.1A left).  To determine if this co-expression was 
also present in human disease, sections of cartilage from human osteoarthritic 
patients were also stained for Runx1 and VCAM-1.  Interestingly, neither Runx1 
nor VCAM-1 positive cells were found in the spared lateral compartment (data 
not shown).  However, chondrocytes present in clonal populations on the medial 
side of the joint were positive for both Runx1 and VCAM-1 (Figure 3.1B).  These 
results suggest that Runx1 positive chondrocytes represent a progenitor cell 
population that is capable of responding to cartilage damage. 
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Figure 3.1: Runx1 and VCAM-1 Co-localize in Normal and Osteoarthritic 
Cartilage.  (A) Immunofluorescense for Runx1 [95], VCAM1 (red), and DAPI 
(blue) in articular cartilage on the lateral (spared) and medial (OA) side of the 
knee joint after induction of osteoarthritis in a mouse (40x).  (B) 
Immunofluorescense for Runx1 [95], VCAM1 (red), and DAPI (blue) on sections 
from the medial (OA) side of a human osteoarthritic knee joint (40x).   
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Runx1 Co-localizes with Markers of Proliferation in Osteoarthritic Cartilage.   
 
Runx1 positive cells are detected in chondrocyte clones in human osteoarthritis, 
and in clusters of cells at the periphery of OA lesions in the mouse, both 
populations of cells that may be a result of proliferation.  To test if these Runx1 
positive cells also express markers of proliferation, sections of mouse and human 
OA knees were stained for Runx1 and proliferation markers.  
Immunohistochemical analysis showed PCNA, a marker for proliferation, to be 
present in chondrocyte clusters at the periphery of OA lesions (Figure 3.2A, right) 
in a mouse model of osteoarthritis.  Immunoflourescense analysis of human 
sections showed that both Runx1 and Ki-67, an additional marker for 
proliferation, were co-expressed in the clones of human OA (Figure 3.2B).   
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Figure 3.2: Runx1 and proliferation markers are expressed in the same 
population of Cells in OA Lesions.  
(A) Immunohistochemistry for Runx1 (left) and PCNA in articular cartilage of a 
mouse after OA-inducing surgery (200x). Positive cells are denoted by arrows.  
(B) Immunofluorescense for Runx1 [95], Ki-67 (red) and Dapi (blue) in human 
osteoarthritic cartilage from the medial (OA) compartment (40x). 
 
 
 
Runx1 does not Promote Proliferation in an in vitro Chondrocyte Model. 
Because Runx1 is associated with proliferating cells in osteoarthritic cartilage, 
the hypothesis that Runx1 overexpression may result in increased proliferation in 
an in vitro chondrocyte model was tested.  ATDC5 cells overexpressing Runx1, 
or an empty vector control were plated at an equivalent density, and counted 
every 12 hours for 2 days.  In three independent wells, there was no significant 
change in cell number due to Runx1 overexpression at any of the time points, 
indicating that proliferation rates are the same for all cells tested (Figure 3.3A).   
Additionally, cell morphology did not change with overexpression of Runx1 
(Figure 3.3B).   
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Figure 3.3: Runx1 does not Affect Cell Proliferation in ATDC5 Cells 
(A) Graph of cell number 12, 24, 36, and 48 hours after overexpression of Runx1 
proteins in ATDC5 cells. Graph average counts from three independent wells, 
and error bars represent standard deviation. (B) Phase images of ATDC5 cells 
24 hours after overexpression of Runx1 proteins.  
 
Promoter Analysis of Genes Differentially Regulated during Chondrogenesis 
 To gain insight into the potential role of Runx1 in cartilage, a candidate 
gene approach was used to identify its potential downstream targets.  A 2005 
study that profiled expressed cDNA by a microarray analysis identified 144 genes 
that were upregulated 10-fold or greater, and 66 genes that were downregulated 
10-fold or greater during in vitro chondrocyte differentiation of limb bud 
micromass cultures, with some data validated in ATDC5 cells [109].  To test the 
hypothesis that these genes had the potential to be regulated by Runx proteins, 
each of the 210 genes that were differentially regulated during chondrogenesis 
0200000400000
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was searched for Runx binding sites in their proximal promoter (2kb from the 
transcription start site to 200bp after the transcription start site).  The consensus 
Runx binding site (ACC A/G C A/T) or its complement (T/A G C/T GGT) was 
found in 131 genes that are upregulated and 61 genes that are downregulated 
during chondrogenesis.  Table 3.1 summarizes the results.  The 18 remaining 
genes contained no Runx binding sites in their proximal promoters. The number 
of Runx sites ranged from as few as one to as many as ten, indicating that most 
genes that are differently expressed during chondrogenesis have the potential to 
be directly regulated by Runx proteins.   To determine if Runx1 regulated some 
of the genes, ATDC5 cells transfected with either empty vector controls or a 
Runx1 overexpression vector were analyzed for differential regulation of some of 
these genes that also play a role in osteoarthritis.  Samples of these cells from 3 
independent experiments were analyzed in duplicate wells by qPCR.  For this 
preliminary experiment, genes that haven been previously shown to have 
functions in OA were chosen for analysis. These genes were Cp, BMP7, Sox11, 
Wisp2, Dcn, and Cxcl10.  Additionally, ItgB2 was chosen as a representative 
gene containing the maximum number of Runx binding sites in its proximal 
promoter found during the initial analysis.   None of these genes showed a 
significant change in mRNA levels with overexpression of Runx1 (n=3 
independent experiments with duplicate wells for RT-PCR analysis from each 
experiment).   
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Table 3.1. Identification of Runx Binding Sites in Genes Differentially Expressed during 
Chondrocyte Maturation 
Gene Name Gene Description Chromosome Fold 
Change 
# of 
Runx 
Sites 
Location of Runx 
Sites 
Cxcl16 Chemokine (C-X-C motif) ligand 16 11 10 7 -1275, -992, -781,         
-514, -118, +26, +163 
Avil Advillin 10 10 2 -351, -25 
Sepp1 Selenoprotein P, plasma, 1 15 10 2 -1952, -1621 
Fgf21 Fibroblast growth factor 21 7 11 2 -1572, -817 
Gpr49 G protein-coupled receptor 49 10 11 3 -1159, -1012, -948 
Igfbp6 Keratin complex 2, basic, gene 8 15 11 3 -1972, -1485, -644 
Dspg3 Dermatan sulphate proteoglycan 3 10 11 6 -1893, -847, -589,         
-540, -374, +37 
Cilp2 Cartilage intermediate layer protein 
2 
8 11 3 -435, -418, -129 
Ddx60 DEAD box polypeptide 60 8 11 7 -1994, -1198, -1115,           
-1018, -1009, +71, 
+141 
Dcn Decorin 10 11 2 -1683, -397 
Tcfec Transcription factor EC 6 11 4 -1290, -990, -221, -134 
Esm1 Endothelial cell-specific molecule 1 13 11 1 -1244 
Emp2 Epithelial membrand protein 2 16 11 1 -1928 
Cpxm2 Carboxypeptidase X 2 (M14 family) 7 11 2 -764, -742 
Vit Vitrin 17 11 2 -741, +117 
Ptpns Protein tyrosine phosphatase, non 
receptor type substrate 1 
2 11 2 -1658, -795 
Serpina3n Serine (or cysteine) protease 
inhibitor, clade A, member 3N 
12 11 6 -1699, -977, -793,        
-739, +122, +271 
Krtdap Keratinocyte differentiation 
associated protein provided 
7 11 6 -1971, -1612, -1255,     
-650, -425, +75 
Ctss Cathepsin S 3 12 4 -1524, -785, -684, +95 
Cxcl15 Chemokine (C-X-C motif) ligand 15  12 1  
Chrdl1 Chordinlike 1 X 12 6 -1921, -1713, -1017,     
-560, -392, -77 
Lmo2 LIM domain only 2 2 12 3 -1756, -1041, -914 
Hpgd Hydroxyprostaglandin 
dehydrogenase 15 [36] 
8 12 2 -1645, -682 
Fndc1 Fibronectin type III domain 
containing 1 
17 13 1 -1124 
Wisp2 WNT1 inducible signaling pathway 
protein 2 
2 13 8 -1498, -1392, -1209,     
-765, -711, -437, -46, 
+189 
C1s Complement component 1, s 
subcomponent 
6 13 1 -1314 
Ccr5 Chemokine (C-C motif) receptor 5 9 13 6 -1906, -1837, -1694,          
-1381, -1316, -1098 
C1qb Complement component 1, q 
subcomponent, beta polypeptide 
4 13 1 -942 
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Table 3.1 Continued 
Gene Name Gene Description Chromosome Fold 
Change 
# of 
Runx 
Sites 
Location of Runx 
Sites 
Plek Pleckstrin 11 13 5 -1590, -1047, -674,      
-372, +103 
Tspan17 Tetraspanin 17 13 14 5 -1990, -1836, -1019,     
-682, +23 
Rassf5 Ras association (RalGDS/AF-6) 
domain family 5 
1 14 4 -1657, -1506, -1031,    
-877 
Alox5ap Arachidonate 5-lipoxygenase 
activating protein 
5 14 4 -1836, -1164, -647,      
-498 
AK018126 RIKEN cDNA 6330406I15 gene 5 14 1 -140 
Blvrb Biliverdin reductase B (flavin 
reductase (NADPH)) 
7 15 6 -1742, -1497, -1025,     
-927, -576, -389 
Fxyd2 FXYD domain-containing ion 
transport regulator 2 
9 15 5 -1952, -736, -499,        
-168, +126 
Slfn8 Schlafen 8 11 15 4 -1851, -504, -19, +12 
Casp11 Caspase 11, apoptosis-related 
cysteine proteiase 
9 15 4 -1961, -1844, -1081,     
-628 
Nr1d1 Nuclear receptor subfamily 1, group 
D, member 1 
11 15 4 -1511, -1395, -607,       
-401 
Ugt1a1 UDP-glucuronosyltransferase 1 
family, member 1 
 15 5 -1552, -741, -529,        
-460, +48 
Jcam2 Junction adhesion molecule 2 16 15 5 -1538, -849, -841,        
-237, -118 
Car6 Carbonic anhydrase 6  16 4 -1552, -1187, -780,       
-606 
Ebi3 Epstein-Barr virus induced gene 3 17 16 4 -1893, -1292, -1187,     
-184 
Ms4a7 Membrane-spanning 4-domains, 
subfamily A, member 7 
19 16 8 -1437, -1397, -1346,          
-1273, -1250, -787,      
-444, -361 
C1qg Complement component 1, q 
subcomponent, gamma polypeptide 
4 16 5 -1470, -642, -338,         
-109, +19 
Fermt3 Fermintin family homolog 3 19 16 5 -1993, -903, -260, -61,       
-24 
C207 
antigen 
Langerin 6 16 4 -1813, -1492, -1364,     
-422 
Fcgr3 Fc receptor, IgG, low-affinity Iib 1 16 10 -1830, -1714,                      
-1171, -1152, -1067,    
-599, -481, -137, +24, 
+74 
Gpnmb Glycoprotein (transmembrane) nmb 6 17 4 -1880, -1206, -711,      
-175 
Slpi Secretory leukocyte protease 
inhibitor 
2 17 4 -1126, -1046, -643,      
-628 
Ly86 Lymphocyte antigen 86 13 17 5 -1835, -1598, -1321,          
-1183, -828 
      
57
      
Table 3.1 Continued 
Gene Name Gene Description Chromosome Fold 
Change 
# of 
Runx 
Sites 
Location of Runx 
Sites 
Kcnn4 Potassium intermediate/small 
conductance calcium-activated 
channel, subfamily N, member 4 
7 17 10 -1498, -1115, -960,      
-346, -279, -226, -213, 
-190, -102, +11 
Itgbl1 Integrin beta like 1 14 17 2 -1676, -1456 
Csf1r Colony stimulating factor 1 receptor 18 17 6 -1462, -1259, -907,      
-560, -293, +116 
Evi2a Ecotropic viral integration site 2a 11 17 6 -1181, -969, -707,        
-653, -376, +87 
Vav Vav 1 oncogene 17 18 3 -1207, -293, -1 
Slc1a6 Solute carrier family 1, member 6 10 18 4 -1653, -1560, -334,      
-262 
Prg Proteoglycan, secretory granule  18 4 -1700, -1318, -809,      
-312 
Cp Ceruloplasmin 3 18 3 -1605, -832, -491 
Msr1 Macrophage scavenger receptor 1 8 19 3 -1657, -850, -322 
Pira6 Paired-Ig-like receptor A6 7 19 4 -1948, -1917, -979,      
-314 
Thbs4 Thrombospondin 4 13 19 2 -1820, -1792 
Nt5e 5' nucleotidase, ecto 9 19 3 -638, -549, -493 
Itgb2 Integrin beta 2 10 19 10 -1894, -1787, -1697,          
-1205, -1068, -1014,              
-1003, -663, -376, +124 
P2ry6 Pyrimidinergic receptor P2Y, G-
protein coupled, 6 
7 19 2 -750, -390 
LOC226421 RIKEN cDNA 5430435G22 gene 1 19 9 -831, -813, -796,                
-770, -765, -753, -735,             
-722, -691 
Fyb FYN-binding protein 15 19 1 -311 
Clecsf10 C-type (calcium-dependent, 
carbohydrate recognition domain) 
lectin, superfamily member 10 
6 19 4 -1995, -1456, -446,      
-420 
Lpl Lipoprotein lipase 8 20 2 -1822, -1274 
Cd68 CD68 antigen 11 20 2 -1883, +123 
Lcp1 Lymphocyte cytosolic protein 1 14 20 4 -1457, -517, +67, +115 
Icsbp Interferon consensus sequence 
binding protein 1 
8 20 1 -889 
Cxcl10 Chemokine (C-X-C motif) ligand 10 5 21 2 -623, +23 
Tnfaip2 Tumor necrosis factor, alpha-
inducen protein 2 
12 21 5 -998, -866, -197, -2,      
-115 
Cxcl4 Chemokine (C-X-C motif) ligand 4 5 21 2 -1684, -354 
Hcph Hemopoietic cell phosphatase 6 22 1 -1988 
Ci1 Solute carrier family 15, member 3 19 22 6 -1826, -824, -407,        
-143, -24, +51 
Lrrc33 Leucine-rich repeat containing 33 16 22 5 -1837, -1692, -1441,     
-854, -174 
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Table 3.1 Continued 
Gene Name Gene Description Chromosome Fold 
Change 
# of 
Runx 
Sites 
Location of Runx 
Sites 
Ms4a6d Membrane-spanning 4-domains, 
subfamily A, member 6d 
19 22 5 -1975, -1369, -1208,    
-915, -562 
Ndr1 N-myc downstream regulated 1 15 22 5 -957, -645, -365, -294, 
+100 
Tyrobp TYRO protein tyrosine kinase 
binding protein 
7 23 3 -1274, -711, +23 
Sp100 Nuclear antigen Sp100 7 23 2 -1785, -583 
Stab1 Stabilin1 14 23 3 -1502, -713, -490 
Laptm5 Lysosomal-associated protein 
transmembrane 5 
14 23 7 -1847, -1233, -953,      
-813, -789, -757, +18 
Ccl9 Chemokine (C-C motif) ligand 9 11 23 9 -1990, -1839, -1785,    
-991, -725, -709, -591, 
-472, -352 
Fam26e Family with seuence similarity 26, 
member E gene 
10 24 4 -1540, -1488, -1252,    
-657 
Adh7 Alcohol dehydrogenase 7 (class IV), 
mu or sigma polypeptide 
3 24 8 -1380, -1349, -1261,    
-433, -410, -354, -130, 
+75 
C1qa Complement component 1, q 
subcomponent, alpha polypeptide 
4 24 4 -949, -366, -104, +106 
Comp Cartilage oligometric matrix protein 8 24 5 -1483, -1215, -921,      
-517, -231 
Cxcl5 Chemokine (C-X-C motif) ligand 5 5 24 3 -1746, -1355, -443 
Ptprc Protein tyrosine phosphatase, 
receptor type, C 
1 25 6 -1897, -1042, -760,      
-586, -141, +33 
Cd53 CD53 antigen 3 25 2 -1103, -250 
Prelp Proline arginine-rich end leucine-
rich repeat 
1 25 1 -666 
Apobec1 Apolipoprotein B editing complex 1 6 25 6 -1515, -1089, -668,      
-626, -246, +74 
Clecsf8 C-type (calcium-dependent, 
carbohydrate recognition domain) 
lectin, superfamily member 8 
6 26 3 -1828, -1677, -715 
C1r Complement component 1, r 
subcomponent 
6 27 2 -1912, -1058 
Clec4a2 C-type lectin domain, family 4, 
member a2 gene 
6 27 3 -1178, -731, -297 
Dock2 Dedicator of cyto-kinesis 2 11 27 2 -1698, -881 
Rarres2 Retinoic acid receptor responder 2 6 29 2 -1736, +27 
Csf2rb1 Colony stimulating factor 2 receptor 15 29 3 -1927, -745, -314 
Bst1 Bone marrow stromal cell antigen 1 5 29 1 140 
Lst1 Leukocyte-specific transcript 1 17 31 7 -1693, -1665, -1450,           
-1216, -849, -316, -283 
Ccl3 Chemokine (C-C motif) ligand 3 11 32 6 -1572, -1040, -438,       
-389, -145, +90 
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Table 3.1 Continued 
Gene Name Gene Description Chromosome Fold 
Change 
# of 
Runx 
Sites 
Location of Runx 
Sites 
Pirb Paired-Ig-like receptor B 7 32 6 -1810, -1790, -1744,          
-1713, -422, -277 
Fcer1g Fc receptor, IgE, high affinity I, 
gamma polypeptide 
1 33 5 -1732, -1185, -190,      
-125, +25 
Adam23 A disintegrin and metalloprotease 
domain 23 
1 35 2 -1194, -552 
Mpeg1 Macrophage expressed gene 1 19 35 3 -1832, -1078, -529 
Hp Haptoglobin 8 37 6 -1736, -1545, -955,      
-938, -158, -43 
Car9 Carbonic anhydrase 9 4 38 1 -111 
Epsti1 Epithelial stromal interaction 1 14 39 6 -1734, -971, -902,         
-843, -672, +142 
C1qr1 Complement component 1, q 
subcomponent, receptor 1 
2 42 4 -1431, -1369, -244, +8 
Fabp4 Fatty acid binding protein 4, 
adipocyte 
3 43 2 -1973, -999 
Evi2b Ecotropic viral integration site 2b 11 45 6 -1231, -1019, -757,       
-703, -426, +37 
Ccl6 Chemokine (C-C motif) ligand 6 11 45 7 -1121, -1102, -1089,            
-1068, -951, -624, -185 
Pfc Properdin factor, complement X 47 3 -1318, -681, -552 
Igsf6 Immunoglobulin superfamily, 
member 6 
7 47 3 -1006, -523, +133 
Xdh Xanthine dehydrogenase 17 48 4 -1496, -1010, -897,      
-773 
Ncf1 Neutrophil cytosolic factor 1 5 51 7 -1550, -1073, -987,       
-839, -422, -111, -16 
Ifi203 Interferon-activated gene 203 1 53 3 -851, -753, -93 
Ifi202b Interferon-activated gene 202b 1 53 2 -1805, -1613 
Trem2b Triggering receptor expressed on 
myeloid cells 2b 
17 57 4 -1772, -1357,                       
-1303, -1073 
Psmb8 Proteosome subunit, beta type 8 17 57 2 -1539, -1337 
Cd48 CD48 antigen 1 59 3 -1903, -93, -79 
Ifi205 Interferon-activated gene 205 1 64 5 -798, -530, -393, -176, 
-6 
Lyzs Lysozyme 10 64 3 -1708, -752, -17 
Fgl2 Fibrinogenlike protein 2 5 68 4 -1866, -1209, -548, 
+128 
Casp1 Caspase 1 9 80 3 -1815, -951, +104 
Fcgr2b Fc receptor, IgG, low-affinity Iib 1 80 3 -1187, -818, +114 
Sod3 Superoxide dismutase 3, 
extracellular 
5 85 9 -1907, -1845,                      
-1800, -1330, -1295,             
-1253, -583, -115, -47 
Pkib Protein kinase inhibitor beta, cAMP 
dependent, testis specific 
10 105 2 -923, -116 
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Gene Name Gene Description Chromosome Fold 
Change 
# of 
Runx 
Sites 
Location of Runx 
Sites 
Mmp13 Matrix metalloproteinase 13 9 126 5 -1223, -908, -604,        
-542, -40 
Ibsp Integrin-binding sialoprotein 5 241 1 -1224 
Tmem46 Transmembrane protein 4 14 -10 9 -1940, -1643, -1416,             
-1289, -1050, -863,      
-501, -376, -117 
Pitx2 Pairedlike homeodomain 
transcraption factor 2 
3 -10 4 -1891, -1283, -252,      
-211 
Nespas Neuroendocrine sceretory protein 
antisense 
2 -10 6 -1715, -1373, -846,       
-540, -154, +30 
Nmyc1 Neuroblastoma myc-related 
oncogene 1 
12 -11 4 -1980, -877, -660, -570 
Ccni Cyclin I 5 -11 1 -1345 
Cd24a CD24a antigen 10 -11 3 -1226, -986, -313 
Ank1 Ankyrin 1, erythroid 8 -11 7 -1473, -1378, -1147,           
-1073, -711, -605, -332 
Sart3 Squamous cell carcinoma antigen 
recognized by T-cells 3 
5 -11 6 -1890, -1683, -1290,          
-1115, -275, -144 
Rxrg Retinoid X receptor gamma 1 -12 6 -1759, -1484, -762,       
-569, -481, -16 
Nipsnap 1 4-nitrophenylphosphatase domain 
and non-neuronal SNAP25-like 
protein homolog 1 (C. elegans) 
11 -12 5 -1689, -1633, -1333,    
-676, +149 
Asb4 Ankyrin repeat and SOCS box-
containing protein 4 
6 -13 2 -1670, -646 
Pcdh8 Protocadherin 8 14 -13 2 -1526, -1213 
Fjx1 Four-jointed box 1 (Drosophila) 2 -13 3 -1935, -1841, -389 
Ttn Titin 2 -13 6 -1969, -1964, -713,      
-245, +55, +73 
Bex2 Brain expressed X-linked 2 X -14 4 -1437, -1147, -169, -81 
Gdf5 Growth differention factor 5 2 -15 2 -1996, -330 
Peg3 Paternally expressed 3 7 -15 4 -1535, -890, -667, -559 
Tnnt1 Troponin T1, skeletal, slow 7 -15 7 -1504, -1225, -1078,    
-730, -705, -695, -324 
Sln Sarcolipin 9 -15 2 -1410, -235 
Myod1 Myogenic differentiation 1 7 -16 3 -1739, -1011, +37 
Tmem100 Transmembrane protein 100 11 -16 4 -1790, -860, -791, -34 
Myla Myosin, light polypeptide 4 11 -16 3 -1728, -883, -594 
Chrna1 Cholinergic receptor, nicotinic, 
alpha polypeptide 1 (muscle) 
2 -17 2 -1935, -595 
Tmem8c Transmembrane protein 8c 2 -18 5 -1492, -863, -642, -42, 
+54 
Igsf9 Immunoglobulin superfamily, 
member 9 
1 -19 4 -1417, -1022, -976, 
+135 
Acta1 Actin, alpha1, skeletal muscle 8 -19 3 -1794, -1170, -478 
Pde9a Phosphodiesterase 9A 17 -20 1 -1169 
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Gene Name Gene Description Chromosome Fold 
Change 
#  of 
Runx 
Sites 
Location of Runx 
Sites 
Mybph Myosin -binding protein H 1 -21 3 -720, -585, -154 
Sema6a Sema domain, transmembrane 
domain [110],and cytoplasmic 
domain, (semaphorin) 6A 
1 -21 3 -1858, -655, -178 
Sox11 SRY-box containing gene 11 12 -21 2 -1081, -755 
Lrp4 Low-density lipoprotein receptor-
related protein 4 
2 -22 2 -1703, -930 
Il17b Interleukin 17B 18 -22 1 -763 
Gcat Glycine C-acetyltransferase (2-
amino-3-ketobutyrate-coenzyme A 
ligase) 
15 -22 2 -416, -365 
Sostdc1 Sclerostin domain containing 1 12 -22 5 -1817, -685, -667,        
-274, +162 
Siat7c Sialyltransferase 7 ((alpha-N-
acetylneuraminyl 2,3-
betagalactosyl-1,3)-N-acetyl 
galactosamidine alpha-2,6-
siayltransferase) C 
3 -24 3 -477, -207, -56 
BC005730 RIKEN cDNA A330049M08 gene 4 -26 2 -1998, -679 
Cacna1s Calcium channel, voltage-
dependent, L-type, aplha 1s subunit 
1 -26 2 -1302, -1203 
Tnni2 Troponin L, skeletal, fast 2 7 -26 4 -1580, -1349, -774,      
-615 
Bcl11a B-cell CLL/lymphoma 11A (zinc 
finger protein) 
11 -26 2 -1372, -1343 
Prom1 Prominin 1 5 -26 5 -1270, -1174, -856,      
-759, -703 
Hba-a1 Hemoglobin alpha, adult chain 1 11 -28 2 -807, -198 
Mb Myoglobin 15 -28 4 -1404, -837, -95, -55 
Grip1 Glutamate receptor-interacting 
protein 1 
10 -29 5 -1825, -1472, -1122,           
-1094, -1072 
Tncc Troponin C, cardiac/slow skeletal 14 -30 5 -1637, -1390, -1135,     
-75, +63 
Chrng Cholinergic receptor, nicotinic, 
gamma polypeptide 
1 -36 6 -696, -675, -492,                
-378, -367, -142 
Csaq2 Calsequestrin 2 3 -38 4 -1637, -1295, -893,      
-626 
Actn2 Actinin alpha 2 13 -38 7 -1972, -1566, -1429,          
-1289, -1104, -60, +91 
Nnat Neuronatin 2 -40 5 -1991, -1885, -1332,          
-1282, -1071 
BMP7 Bone morphogenic protein 7 2 -40 3 -1675, -681, -175 
Actc1 Actin, alpha, cardiac 2 -42 2 -1312, -1279 
Dusp9 Dual specificity phosphatase 9 X -43 2 -1274, -650 
Dcx Doublecortin X -44 1 -1691 
Rex3 Reduced expression 3 X -50 2 -1578, -1153 
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Lrrn1 Leucine-rich repeat protein 1, 
neuronal 
6 -84 6 -742, -685, -468, -92,    
-54, +120 
Myog Myogenin 18 -85 3 -541, -530, -524 
Tnnt2 Troponin T2, cardiac 1 -98 3 -1787, -954, -856 
Tnni1 Troponin I, skeletal, slow 1 1 -111 1 -1672 
Mylpf Myosin light chain, 
phosphorylatable, fast skeletal 
muscle 
7 -141 4 -1553, -1176, -909,      
-389 
Hbb-y Hemoglobin Y, betalike embryonic 
chain 
7 -245 1 +15 
Myh3 Myosin, heavy polypeptide 3, 
skeletal muscle, embryonic 
11 -392 6 -1375, -869, -648,        
-344, -94, -39 
Mylf Myosin, light polypeptide 1 1 -339 7 -1895, -1766, -1235,     
-797, -743, -153, -102 
 
 
 
Table 3.1 Identification of Runx Binding Sites in Genes Differentially 
Expressed during Chondrocyte Maturation 
Genes that are differentially expressed during chondrogenesis and have Runx 
binding sites in their proximal promoters are listed in order of fold change in 
expression between proliferating and hypertrophic chondrocytes (a positive 
number indicates upregulation during chondrogenesis and a negative number 
indicates downregulation).  The locations of the Runx sites are listed relative to 
the transcription start site. This table is adapted from [109]. 
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Conclusion 
 
In characterizing the clonal populations of Runx1 positive cells in 
osteoarthritic cartilage, it was discovered that they also express VCAM1, a 
marker for mesenchymal progenitor cells, and the proliferation markers Ki67 and 
PCNA.  As stated above, Runx1 is involved in cell proliferation in hematopoietic 
cells [105], and it is possible that it contributes to the regulation of mesenchymal 
progenitor cells in response to articular cartilage damage.  Although Runx1 is 
associated with markers of proliferation, our in vivo studies do not show that the 
increased proliferation rates in cartilage cells are a result of Runx1 expression.   
The in vitro experiments show that Runx1 does not cause increased proliferation 
rates in ATDC5 cells.  This is possibly due to the fact that ATDC5 cells already 
proliferate at a rapid rate.  It is possible that an increase in Runx1 in an already 
rapidly proliferating cell line would not be enough to increase proliferation rates 
further.  Recent data from our laboratory shows that MEFs with decreased levels 
of Runx1 proliferate more slowly than their wild-type counterparts.  A knockdown 
of Runx1 in ATDC5 cells may show decreased proliferation as well.  Additional 
studies need to be done in a cell line that is more representative of articular 
chondrocytes, and these experiments should be repeated in Runx1 expressing 
cells isolated from immature cartilage tissues such as MEFs or immature bovine 
articular cartilage before any conclusions can be drawn. To try to gain insight into 
genes that are potential downstream targets of Runx1 in cartilage, using a 
published gene profile of chondrocyte expressed genes [109], the sequence of 
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the proximal promoter of each gene as published in GenBank was examined 
manually for all variations of consensus Runx binding sites 5’-3’ 
(A/G)ACC(A/G)C(A/T).   The purpose of this was to establish a population of 
candidate genes that are both expressed in cartilage, and have the potential to 
be regulated by Runx1.  Candidate genes were chosen based on their role in 
osteoarthritis.  2 genes that are upregulated, 2 genes that are downregulated, 
and 2 genes that may be protective in OA were chosen for preliminary analysis, 
in addition to a gene that had 10 Runx binding sites in its promoter.  Cp and Dcn 
are upregulated during the disease process of OA [111, 112].  Sox11 and Wisp2 
are downregulated in response to mechanical strain [113, 114]. BMP7 and 
Cxcl10 were chosen for their potential protective effect during osteoarthritis.  
BMP7 decreases joint inflammation at low concentrations while Cxcl10 
stimulates progenitor cell migration [115, 116].  In ATDC5 cells, none of these 
genes showed changes in expression as a result of overexpression of Runx1.  
As with the proliferation studies, it is important to confirm these findings in 
primary chondrocytes.   
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CHAPTER IV: 
Runx Functions in Cartilage 
Pilot Studies: Identifying Novel Mechanisms Runx Proteins in Regulation of 
Protein Synthesis and Epigenetic Control of Chondrogenesis 
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Abstract 
In addition to functioning as phenotypic transcription factors, Runx genes have 
been shown to promote differentiation by controlling cell cycle progression and 
global protein synthesis in some cells.  Changes in protein synthesis rates are 
associated with both cell proliferation and cellular hypertrophy – both processes 
that take place during chondrogenesis.  To determine if Runx proteins regulate 
protein synthesis, Runx1, Runx2, or Runx3 was overexpressed in a 
chondrogenic cell line and assayed transcription levels of ribosomal machinery 
and protein synthesis rates by 35S incorporation.  Preliminary experiments show 
that Runx1, Runx2, and Runx3 overexpression do not cause changes in pre-
rRNA or 28S levels and do not cause changes in protein synthesis rates.  
Additionally, a preliminary experiment shows that Runx proteins are not 
associated with rDNA repeats in ATDC5 cells at any stage during in vitro 
chondrocyte differentiation.  
Runx1, Runx2, and Runx3 are all expressed in growth plate cartilage 
during distinct stages of chondrocyte maturation.  While Runx2 is well known to 
control genes expressed during chondrocyte hypertrophy, the functions of Runx1 
and Runx3 during this process are less well understood. Immunofluorescense 
studies showed that Runx2, but not Runx1 or Runx3, remains bound to DNA 
throughout mitosis, indicating that it has the potential to function epigenetically 
during chondrogenesis by bookmarking its target genes throughout the cell cycle, 
for later expression in post-proliferative hypertrophic chondrocytes. 
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Introduction 
Regulation of protein synthesis is an important factor in the determination 
of cellular growth rates, and the amount of protein per cell contributes to cell size.  
The cellular protein content can be controlled by changing rates of protein 
synthesis and/or rates of protein turnover [117].  The control of global protein 
synthesis is determined by the amount of ribosomes available for translation, and 
this is directly controlled by ribosomal DNA (rDNA) transcription [118].  The 
ribosome is composed of a 40S subunit containing 18S rRNA and approximately 
33 proteins, and a 60S subunit containing 5S, 28S, and 5.8s rRNA and 
approximately 49 proteins [119].  The 18S, 5.8S, and 28S rDNA components are 
transcribed as a single messenger RNA that is then processed into the 
component parts [120].  Transcription of pre-rRNA is controlled by a transcription 
initiation complex consisting of RNA Polymerase I, Selectivity Factor 1 (SL1), and 
Upstream Binding Factor (UBF) which is required for activated transcription 
[118].  All three Runx proteins can bind to ribosomal DNA repeats with UBF to 
control global protein synthesis regulation [121-123].  In osteoblasts, 
overexpression of Runx2 causes a decrease in global protein synthesis by 
repressing rDNA transcription [123]. 
 Increased cell growth can result in either increased proliferation (as cells 
need to double in size before they divide) or cellular hypertrophy.  In proliferating 
cells, an increase in RNA content leads to more rapid cell division [124].  
Additionally, hypertrophy of cardiac myocytes results from an increase in protein 
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synthesis rates, which is directly associated with an increase in rDNA 
transcription [125].  Thus, an increase in ribosomal biogenesis results in an 
increase in overall protein synthesis, which can lead to cell division or 
hypertrophy, depending on cell context.  Therefore in chondrocytes, regulation of 
global protein synthesis rates may be required for both the processes of 
proliferation and hypertrophy. 
 During endochondral bone formation, the chondrocyte goes through 
stages of both rapid division and cellular hypertrophy.  While both of these 
cellular events are regulated by an increase in rates of protein synthesis, there 
must be some other factors regulating the decision between proliferation and 
hypertrophy.  During chondrocyte hypertrophy, C/EBP? directly controls p57Kip2 
expression causing exit from the cell cycle and leading to hypertrophy [126]. The 
protein p57Kip2 is a member of the Cip/Kip family of cell cycle inhibitors and 
functions by binding to cyclin/CDK complexes and inhibiting the transition to 
G1/S phase [127].      
Epigenetics is the process by which genetic information is transferred from 
parent to progeny cell without changes in DNA sequence.  Epigenetics 
commonly refers to gene silencing or gene activation, and there are certain 
epigenetic marks associated with each of these.  For example, DNA 
methyltransferases are enzymes that add methyl groups (CH3) to regions of DNA 
that contain many CpG sites known as CpG islands [128, 129].  The methylations 
of CpG islands result in transcriptional repression by the displacement of 
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transcription factors along with recruitment of proteins involved in gene silencing 
[130].   
 Histone modifications provide another important mechanism of epigenetic 
regulation.  In chromatin, DNA is associated with histones in complexes known 
as nucleosomes, each of which contain ~146 base pairs of DNA wrapped around 
a histone octamer containing two copies each of histones H2A, H2B, H3, and H4 
[131].  The most common types of histone modifications are acetylation and 
methylation.  Table 4.1 (adapted from [132]) lists some common histone 
modifications and their association with either activated or repressed chromatin.  
While this table is generally accurate, there are certain instances where the 
number of methyl groups added to a histone determines its association with 
active or inactive chromatin.  For example, H3K9me1 (one methylation of lysine) 
is associated with active chromatin while H3K9me3 (three methylations of lysine) 
is associated with repressed chromatin [133].  
 In addition to the well-studied DNA methylations and histone 
modifications, “bookmarking” by transcription factors is emerging as a novel 
mechanism for epigenetic regulation of genes.  This involves the retention of 
transcription factors on the promoters of their target genes throughout mitosis, 
when active transcription is not taking place.  It is theorized that the presence of 
transcription factors on target gene promoters poises certain genes for 
transcription immediately upon exit from mitosis [128]. In addition to regulating 
the transcription of their target genes, Runx proteins possess epigenetic 
70
functions.  Runx1, Runx2, and Runx3 remain bound to the promoters of their 
target genes during mitosis, as a novel epigenetic mechanism poising these 
genes so that they can be transcribed upon exit from mitosis [76, 121].  Runx2 is 
also responsible for a number of histone modifications in osteoblasts [134]. 
 Because of the novel functions of Runx proteins in protein synthesis 
control and epigenetic regulation of target genes, this study addresses the 
hypothesis that Runx factors may regulate these functions in chondrocytes.  The 
unique expression of Runx1 in proliferating cells (both in the growth plate and in 
osteoarthritic cartilage) and Runx2 in hypertrophic cells allows for the possibility 
of these transcription factors to regulate protein synthesis during 
chondrogenesis.  In addition, because of their known role as epigenetic 
regulators of their target genes in a variety of cell types, the aim of these 
experiments was to discover whether the Runx proteins also functioned 
epigenetically in chondrocytes.   
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Activating Modifications Repressing Modifications 
Lysine Acetylation CpG Island Methylations 
H3K9, H3K14, H3K18, HeK56  
H4K5, H4K8, H4K13, H4K16 Lysine Methylation 
H2A, H2B H3K9, H3K27 
  H4K20 
Serine/Threonine 
Phosphorylation  
H3T3, H3S10, H3S28 Lysine Ubiquitination 
H2A, H2B H2AK119 
   
Arginine Methylation Lysine Sumoylation 
H3R17, H3R23 H2BK6, H2BK7 
H4R3 H2AK126 
   
Lysine Methylation  
H3K4, H3K36, H3K79  
   
Lysine Ubiquitination  
H2BK120  
 
Table 4.1: Common Epigenetic Modifications and Their Association with 
Activated or Repressed Chromatin (Adapted from [132]) 
 
 
 
Chondrocyte Cell Lines 
One of the major problems with studying chondrocytes is that there are no cell 
lines that reliably reproduce the natural resting chondrocyte or the events of 
chondrogenesis as they happen in vivo.  Many primary chondrocyte cultures de-
differentiate after a few passages, making in vitro experiments difficult.  For the 
pilot experiments discussed in this section, as well as for the proliferation 
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experiments in the previous section, a combination of three different chondrocyte 
differentiation models were used which will be described here. 
 N1511 is a chondrogenic cell line that was isolated from the rib cartilage of 
P53-null mice [135].  The addition of BMP2 and insulin to these cells at 
confluence induces differentiation to hypertrophic chondrocytes [135]. However, 
when BMP2 and insulin were added to the N1511 isolate that was obtained by 
our laboratory, cell death occurred within 48hours. Because this cell line was 
unable to be differentiated, it could not be used to study targets of Runx genes 
during chondrocyte differentiation. This cell line did express a high level of Runx2 
in its proliferating state (Figure 4.1), making it useful for the knockdown 
experiments.  In N1511 cells, proliferation is inhibited by re-introducing p53 [135], 
indicating that the absence of p53 is responsible for the rapid rate of proliferation 
in this cell line. The strong contribution of p53 to proliferation rates in this cell line 
made it a poor choice for studying the contribution of Runx factors to proliferation 
and protein synthesis in chondrogenesis, and may be one of the reasons there 
was no change in protein synthesis machinery observed in response to Runx2 
knockdown. 
 Another cell type that can be used for the study of chondrocyte 
differentiation is the mouse embryonic fibroblast.  These primary cells, when 
grown in high-density micromass cultures, reproducibly go through the stages of 
chondrocyte differentiation [136].   One of the drawbacks to the MEF micromass 
culture of chondrogenic differentiation is that it is difficult to obtain the amount of 
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cells needed for chromatin immunoprecipitation experiments.  Also, it is difficult 
to transfect these cells when they are in high-density micromass cultures, making 
overexpression experiments difficult.  The advantage to these primary cells is 
they can be isolated from different strains of mice.  Thus, the 35S incorporation 
experiments done on these cells are able to compare normal levels of Runx2 to a 
complete Runx2 knockout.  Unfortunately, it is known that Runx2 -/- MEFs do not 
progress to hypertrophic chondrocytes, and therefore these cells can only be 
studied in monolayer culture.   
 The cell line that was used for a majority of this research was ATDC5.  
This is a cell line that is derived from a teratocarcinoma, and is able to mature to 
a chondrocyte that expresses many markers of hypertrophy when plated under 
differentiation conditions in medium containing insulin [137].  However, there is 
debate in the field regarding whether or not these cells actually reach 
chondrocyte hypertrophy, as determined by the expression of Collagen 10.  In 
many studies, including these, Collagen 10 expression is not increased 
substantially during in vitro differentiation.  However, these cells do produce a 
mineralized matrix as evidenced by positive alkaline phosphatase staining.  An 
advantage to these cells is that they are easily transfectable, and that they can 
be differentiated in monolayer, making them a good choice for overexpression 
studies. 
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Materials and Methods 
 
Cell Culture Conditions 
ATDC5 cells were maintained in DMEM/F12 medium supplemented with 2mM L-
glutamine, 100 U/mL penicillin, 100 µg/mL streptomycin, 10% FBS, 10µg/mL 
transferrin, and 3x10-8M sodium selenite.  N1511 cells were maintained in α-
MEM supplemented with 2mM L-glutamine, 100 U/mL penicillin, 100 µg/mL 
streptomycin, and 10% FBS.  Both cell lines were cultured at 37oC in the 
presence of 5% CO2. 
For ATDC5 differentiation, cells were plated at a concentration of 350,000 
cells/plate in a 100mm plate, 133,636 cells/plate in a 60mm plate, or 24,182 
cells/well in a 6-well plate.  Cells were maintained in DMEM/F12 medium 
supplemented with 2mM L-glutamine, 100 U/mL penicillin, 100 µg/mL 
streptomycin, 10% FBS, 10µg/mL transferrin, and 3x10-8M sodium selenite for 7 
days, with medium changes 4 and 6 days after plating.  7 days after plating, the 
medium was changed to DMEM/F12 supplemented with 2mM L-glutamine, 100 
U/mL penicillin, 100 µg/mL streptomycin, 2% FBS, 10µg/mL transferrin, and 
3x10-8M sodium selenite, and 10µg/mL insulin.  Medium was changed every 2-3 
days during the time course, and cells were harvested for up to 28 days.   
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Isolation of Mouse Embryonic Fibroblasts 
For isolation of MEFs, mice with a targeted disruption of Runx2 on a C57/Bl6, 
Dba/2 background were used [36].  As mice homozygous for the mutation die at 
birth, heterozygous mice were bred to obtain litters containing wild type, 
heterozygous, and Runx2-/- embryos.  Pregnant mice were sacrificed at day 12.5 
by CO2 asphyxiation and cervical dislocation.  The abdomen was opened and the 
uterus was removed.  Single embryos were removed by opening the uterus wall 
and puncturing the embryonic sac.  Embryos were washed with phosphate 
buffered saline (PBS) and digested by adding 1mL of 0.25% Trypsin-EDTA, 
passing each embryo through an 18Ga needle 20 times, and incubating the 
resulting cell suspension for 15 minutes at room temperature.  Nine mL of DMEM 
+ 2mM L-glutamine, 100 U/mL penicillin, 100 µg/mL streptomycin, and 15% FBS 
were added to each sample and the mixture was plated on a 100mm plate and 
cultured at 37oC in the presence of 5% CO2.  After 24 hours, cells were washed 
with PBS to remove the non-adherent cells and given fresh growth medium.  
Medium was changed every other day and cells were passaged 1:5 at 70% 
confluence. 
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Runx Overexpression 
For Runx overexpression, vectors containing full-length mouse Runx1 and Runx3 
in a pcDNA backbone, and full-length mouse Runx2 in a pLENTI CMV/TO GFP-
Zeo DEST backbone were generated.  For transformation experiments, ATDC5 
cells were plated at 100,000 cells/well in a 6-well plate or 666,666 cells/plate in a 
100mm plate.  Cells were transfected with either an empty vector, or a vector 
containing Runx1, Runx2, or Runx3 using X-treme gene transfection reagent 
(Roche, Mannheim, Germany) according to the manufacturer’s protocol, using 
1µg of plasmid and 3µL of transfection reagent.  Cells were grown up to 48h 
post-transfection and cells were harvested at the time points specified below.   
 
Quantitative Real Time PCR Analysis 
For RNA preparation, cells from a 100mm plate were rinsed with PBS, and then 
harvested in 1mL Trizol.  RNA isolation was carried out by phenol/chloroform 
extraction followed by ethanol precipitation.  DNA contamination was removed 
using the DNase-free RNA kit [138] according to the manufacturer’s 
specifications.  Nucleic acid quantification was carried out using a Nano-drop 
spectrophotometer, and RNA purity was assessed using the 260/280 ratio.  One 
µg of RNA was reverse transcribed into cDNA with the First Strand cDNA 
synthesis kit (Invitrogen) using random hexamers according to the 
manufacturer’s protocol.  RT-PCR was performed on a 7300 Real Time PCR 
System (Applied Biosystems).  Samples were run in duplicate using 20ng of 
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cDNA, 5µM forward and reverse primer, and SybrGreen Master Mix (Bio Rad) in 
a 25 µL reaction. Primers used can be found in Table 4.2. 
 
Gene Forward Primer Reverse Primer 
Cp CATGGGGTAACGTACACCAAG GCACATACACATACTGTTGTCCG 
Dcn  CCCTACCGATGCCAGTGTC GCAGGTCTAGCAAGGTTGTGT 
Wisp2  TGCCCCGAGTGGGTGTGTGA GGGCCATCGGCAGATGCAGG 
Itgb2  TGCACCAAGTACAAAGTCAGC GCGCAAGGAGTCAGGTTCT 
Cxcl10  CCAAGTGCTGCCGTCATTTTC GGCTCGCAGGGATGATTTCAA 
Sox11  CCCTGTCGCTGGTGGATAAG GGTCGGAGAAGTTCGCCTC 
Bmp7  ACGGACAGGGCTTCTCCTAC ATGGTGGTATCGAGGGTGGAA 
 
Table 4.2: Genes Chosen and Primers used for Quantitative RT-PCR 
Analysis after Runx1 Overexpression 
 
 
 
 
Chromatin Immunoprecipitation 
Chromatin immunoprecipitation experiments were carried out as previously 
described [139]. ATDC5 cells were induced to undergo chondrocyte maturation 
using the differentiation protocol described above.  On days 0 and 7, cells were 
rinsed once in PBS, and 10mL of DMEM/F12 was added back to the plates.  On 
days 14, 21, and 28, cells were rinsed in PBS and treated with Collagenase P for 
5 minutes.  Cells were rinsed once more in PBS and 10mL of DMEM/F12 was 
added back to the plates.   To crosslink proteins and DNA, 1mL of formaldehyde 
solution (50mM HEPES-KOH buffer pH 7-7.5, 100mM sodium chloride, 1mM 
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EDTA, 0.5mM ethylene-glycol-bis (2-aminoethylether)-N-N-N’-N’-tetraacetic acid, 
2.57% (w/v) formaldehyde, in nuclease-free water) was added to each plate and 
plates were incubated for 10 minutes at room temperature.  To quench the 
reaction, 0.5mL of 2.5M glycine was added to each plate and plates were 
incubated at room temperature for 10 minutes.  Plates were washed with ice-cold 
PBS Wash Buffer (0.2µM-filtered PBS, 25µM MG132 (proteasome inhibitor), 1x 
complete EDTA-free protease inhibitor cocktail tablet solution), then harvested in 
500µl of PBS Wash Buffer and transferred to a microcentrifuge tube.  Cells were 
spun at 700xg for 5 minutes at 4oC, resuspended in 1mL ice-cold PBS Wash 
Buffer, and spun again 700xg for 5 minutes at 4oC.  At this point, cells were flash-
frozen in liquid nitrogen and stored at -80oC.   
Cells were thawed and resuspended in 1mL of ChIP Buffer C (10mM Tris-HCl pH 
8.0, 100mM sodium chloride, 1mM EDTA, 1mM ethylene-glycol-bis(2-
aminoethylether)-N-N-N’-N’-tetraacetic acid, 0.1% (w/v) sodium deoxycholate, 
0.5% (w/v) N-lauroylsarcosine sodium salt solution, 25µM MG132, 1x complete 
EDTA-free protease inhibitor cocktail tablet solution, in nuclease free water) and 
cells were allowed to thaw in buffer for 20 minutes on ice.  Cells were sonicated 
as follows: On Time: 1 second, Off Time: 2 seconds, Total On Time: 20 seconds; 
and this program was repeated 3 times with 20 seconds rest between.  After 
sonication, 600U each of HaeIII and PstI-HF were added to each tube and 
incubated for 1h at 32oC.  Following this incubation, 109µL of Triton X-100 
solution was added to each tube (final concentration = 1%).  Tubes were spun for 
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15 minutes at 16,100 x g at 4oC, and supernatants were transferred to a new 
microcentrifuge tube.  One mL of chromatin prep was used for each IP.  5ug of 
antibody were added to each respective tube and cells were placed on a vertical 
rotor at 4oC for 16h.  35µL each of Dynabeads Protein A and Protein G were 
added to each tube, and tubes were placed back on the vertical rotor at 4oC for 5 
hours.  Beads were washed 1x in Buffer C + 1% triton X-100, and 3x in ChIP 
Wash Buffer (50mM HEPES-KOH pH 7-7.5, 150mM lithium chloride solution, 
1mM EDTA, 0.5% (w/v) nonindet P40 solution, 0.25% (w/v) sodium 
deoxycholate, in nuclease-free water), and 1x in TE Buffer (10mM Tris-HcL pH 
8.0, 1% (w/v) SDS solution, in nuclease-free water).  Protein was eluted by 
adding 100uL of ChIP Elution Buffer (100mM sodium bicarbonate, 1% (w/v) SDS, 
in nuclease-free water) and placing tubes on the Micro Tube Mixer for 15 
minutes, and this step was repeated after adding an additional 100uL of ChIP 
elution buffer.  160µL of ChIP Elution Buffer was added to the input sample, and 
all tubes were placed in a 65oC hybridization oven for 16 hours.  200µL of TE 
buffer, and 8µL of RNase A were added to each tube and incubated at 37oC for 2 
hours.  4µL of proteinase K was added to each tube and incubated at 55oC for 2 
hours.  Chromatin was then isolated by adding 400µL phenol/chloroform/isoamyl 
alcohol (25:24:1) solution to each tube, mixing thoroughly, and transferring to a 
MaXtract High Density 2mL tube, and spinning at 10,000rpm for 10 minutes to 
isolate the chromatin in the aqueous phase.  400µL of chloroform/isoamyl alcohol 
(24:1) was added to each tube and spun again at 10,000rpm for 10 minutes.  The 
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aqueous layer was transferred to a new tube and 2µL of glycogen and 40µL of 
3M sodium acetate pH 5.5 was added to each tube and DNA was precipitated 
using isopropanol.  DNA pellets were resuspended in 200µL of nuclease-free 
water.  DNA was quantified and equal concentrations were used in qPCR.  
Antibodies used for IP are described in Figure 4.3.  
 
Metaphase Spreads 
N1511 cells were passaged 1:20 every other day in the medium described 
above.  Cells were blocked in metaphase as previously described [123]. One day 
after passaging, colcemid was added to a 100mm plate at a concentration of 
30ng/µL and plates were incubated for 16h, at which point cells were harvested 
by mitotic shakeoff and pelleted by centrifugation at 1000 RPM for 5 minutes.  
Cells were resuspended in 5mL of 75mM KCl warmed to 37oC and incubated for 
15-20 min at 37oC, and then pelleted by centrifugation at 2500 rpm for 5 min.  
Cells were washed with 1mL PBS, transferred a microcentrifuge tube, and 
pelleted at 4000rpm for 4 minutes.  Cells were washed with an additional 400uL 
of PBS and Cytospun onto slides at 220 rpm for 10 min (~200uL/slide). 
 
Immunofluorescense 
Immunofluorescense experiments were carried out as previously described [123]. 
Slides were dried for 1-2 minutes, washed in PBS for 5 minutes, and fixed in 1% 
formaldehyde for 10 minutes. Cells were washed again for 5 minutes in PBS and 
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permeabilized using 0.25% Triton in PBS for 20 minutes.  Cells were washed 
twice in PBS and then blocked in 0.5% BSA in PBS for 30 minutes.  Cells were 
incubated for 1h at 37oC in primary antibody. Cells were washed three times in 
PBS before incubation for 1h at 37oC in secondary antibody. Cells were washed 
three times in PBS and stained with DAPI solution (1:5000 in triton+PBSA) for 3 
minutes.  Cells were washed with PBSA+triton, PBS, and PBSA before mounting 
with Pro-Long Gold Anti-fade reagent. Slides were visualized on a Zeiss Axioplan 
Fluorescence microscope using MetaMorph imaging software.  Antibodies used 
were Runx1 rabbit polyclonal (1:100, Ab50541, Abcam), Runx2 Mouse 
Monoclonal (1:200), and Runx3 rabbit polyclonal (1:200, Ab 11905, Abcam).  
Secondary antibodies used were Alexa Fluor 488 goat anti-rabbit (1:800) and 
Alexa Fluor 594 goat anti-mouse (1:800). 
 
 
Co-Immunoprecipitation 
N1511 cells were grown to confluence and harvested in 1mL of PBS.  Cells were 
pelleted by centrifugation at 4000rpm for 5 min in a tabletop microcentrifuge.  
Cells were resuspended in 1mL of sonication buffer and incubated on ice for 10 
minutes before sonication at 10% for 5x10 seconds with 20 seconds rest in 
between.  Lysate was separated into equal parts and 4µg of primary antibody 
was added.  Samples were incubated at 4oC for 16 hours before 50µL of Protein 
A/G beads were added.  Samples were incubated at 4oC for an additional 2 
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hours.  Beads were pelleted at 3000rpm for 3 minutes, and washed 4x with 
500µL Wash Buffer.  Samples were eluded with 1X Gel Loading Buffer and 
analyzed by western blot.  Antibodies used for IP were: Runx2 M70 (rabbit 
polyclonal, Santa Cruz) and UBF H300 (rabbit polyclonal, Santa Cruz).  
Antibodies used for Western Blot were Runx2 mouse monoclonal (1:2000) and 
UBF F9 mouse monoclonal (1:1000, Santa Cruz).   
 
35S Incorporation Assays 
ATDC5 cells were plated at 100,000 cells/well in a 6-well plate.  24 hours later, 
cells were transfected with either an empty vector, or a vector containing Runx1, 
Runx2, or Runx3 using X-treme gene transfection reagent according to the 
manufacturer’s protocol, using 1µg of plasmid and 3µL of transfection reagent.  
24 and 48 hours after transfection, cells were washed 2x with PBS, 2mL of pulse-
labeling medium (DMEM –met, -cys, +10% dialyzed FBS + 25mM HEPES) were 
added to each well, and cells were incubated for 15 min at 37oC at 5% CO2.  
Medium was removed from the cells, and 0.5mL of [35S]-methionine working 
solution (pulse-labeling medium + 0.1mCi/mL [35S]-methionine) was added to 
each well.  Cells were incubated for 20 minutes at 37oC at 5% CO2.  Medium was 
removed from the cells, and the cells were washed twice with ice cold PBS and 
scraped into direct lysis buffer (2% sodium dodecyl sulfate, 10mM dithiothreitol, 
10% glycerol, 2M urea, 1x Roche complete proteinase inhibitor, 10mM tris pH 
7.5, 1x MG132).  Total protein content was determined using the Coomassie 
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Plus (Bradford) Assay Kit (Thermo Scientific) according to the manufacturer’s 
protocol.  Equal amounts of protein were loaded on a 4-20% Ready Gel Tris-HCl 
Gel (Biorad).  The gel was dried and exposed for 6-16 hours on BioMax 
Chemiluminescense film to determine 35S incorporation.   
 For MEF experiments, mouse embryonic fibroblasts were isolated as 
described above from wild type or Runx2 -/- embryos.  Cells were plated at 
100,000 cells/plate on 60mm dishes and the pulse labeling was carried out as 
described above, however; cells were harvested in ice-cold PBS instead of direct 
lysis buffer.  10µL of the labeled cell suspension was added to 100µL of 
BSA/sodium azide and placed on ice. 1mL of ice-cold 10% (w/v) TCA solution 
was added to each sample.  The mixture was vortexed and incubated on ice for 
30 minutes.  The suspension was filtered onto 2.5cm glass microfiber filter disks 
and washed twice with 5mL ice-cold 10% TCA and twice with ice-cold ethanol.  
10uL of the labeled cell suspension was also spotted on an additional glass 
microfiber disc.  All discs were allowed to air-dry for 30 minutes.  Discs were 
transferred to 20mL scintillation vials, 5 mL of scintillation fluid was added, and 
radioactivity was measured in a scintillation counter.  The ratio of TCA-
precipitable label to total radioactivity was calculated. 
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Results 
Characterization of Chondrocyte Cell Lines  
Different chondrocyte cell lines and MEFs used in these experiments were 
compared for transcription factor levels to identify the most appropriate cell for 
the Runx functional studies.  Messenger RNA was isolated from each cell type 
for qPCR analysis to determine levels of Runx1, Runx2, and Sox9.  Both ATDC5 
cells and N1511 cells represent more committed chondrocytes when compared 
to MEFs, as evidenced by their Sox9 expression (Figure 4.1).  N1511 cells 
showed very high levels of Runx2 mRNA when compared with the other cell lines 
(Figure 4.1).  To assess the progression of ATDC5 cells through chondrogenesis, 
mRNA was taken weekly for qPCR analysis during ATDC5 differentiation.  Figure 
4.2 shows changes in gene expression during differentiation.  Runx2 and Runx3 
mRNA levels increased 3.5 and 2 fold, respectively during ATDC5 differentiation.  
Interestingly, Runx1 levels remained relatively constant throughout the time 
course, in contrast to what is seen in vivo.  Phenotypic chondrocyte markers also 
showed changes in expression that mimic what is seen during in vivo 
chondrocyte maturation.  Sox9 levels increased 4-fold between days 0 and 7, 
then began to decline during further maturation.  Col2a1 levels began to increase 
on day 7 and reached maximal levels by day 14 (>60 fold increase) before they 
began to decline again at day 28.  Alkaline phosphatase, a marker of 
hypertrophic chondrocytes, continued to increase through ATDC5 differentiation, 
reaching maximal levels at day 28 (>350 fold).  These data indicate that ATDC5 
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cells exhibit the characteristics of proliferating chondrocytes between day 0 and 
7, pre-hypertrophic chondrocytes at day 14, and a cell that expresses many 
hypertrophic markers after day 21. 
 
Figure 4.1: A Comparison of Runx1, Runx2, and Sox9 Expression in in vitro 
Chondrocyte Models  
A comparison of Runx1, Runx2, and Sox9 mRNA levels in MEF cells isolated 
from 2 different mice, ATDC5 cells, and N1511 cells.  The left panel shows a 
close-up version of the panel on the right, due to the high expression of Runx2 in 
N1511 cells. This graph represents one independent experiment and error bars 
represent standard deviation of duplicate samples 
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         Runx1                           Runx2 
Runx3                     Sox9 
 
          Col2a1                  Alk Phos 
 
Figure 4.2: Expression of Runx Proteins and Phenotypic Chondrocyte 
Markers during ATDC5 Differentiation 
Quantitative RT-PCR analysis shows expression of chondrocyte markers during 
ATDC5 differentiation.  Values are normalized to GAPDH and expressed relative 
to day 0 values.  This data is from 1 independent experiment with 2 replicate 
samples analyzed by qPCR.  Error bars represent standard deviation of replicate 
samples. 
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Runx Overexpression does not affect Levels of Protein Synthesis Machinery or 
Change Levels of Global Protein Synthesis. 
As reviewed in the introduction, both cellular proliferation and hypertrophy are 
associated with increases in protein synthesis.  Runx proteins, which regulate 
global protein synthesis in other cell types, are expressed in distinct populations 
of growth plate chondrocytes, and chondrocytes of articular cartilage.  To 
determine if global protein synthesis rates were changed in response to Runx 
overexpression, 35S incorporation assays were performed.  In ATDC5 cells, 
expression of neither Runx1, 2, nor 3 resulted in changes of protein synthesis 
rates (Figure 4.3 B,C), providing preliminary evidence that Runx proteins do not 
control global protein synthesis in this chondrogenic cell line.  Although there was 
no change in protein synthesis rates with overexpression of Runx proteins in 
ATDC5 cells, osteoblasts derived from Runx2-/- mice show increased protein 
synthesis compared to wild-type osteoblasts [123].  To determine if MEFs 
derived from the same mice show increased protein synthesis compared to wild-
type MEFs, 35S incorporation assays were done on MEFs isolated from these 
mice.  In comparison to wild-type MEFs, Runx2 -/- showed no significant change 
in 35S incorporation, indicating comparable protein synthesis rates in both cell 
types (Figure 4.3A).  Additionally, significant knockdown of Runx2 (Figure 4.4A) 
in a chondrocytic cell line that expresses high levels of Runx2 during proliferation 
resulted in no changes to pre-rRNA or 28S levels, although infection with virus 
alone caused a decrease in both levels (Figure 4.4B).  
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A.                 MEF 35S Incorporation                B.        ATDC5 35S Incorporation 
  
 
C.                                      35S Auto Radiograph 
       Control          EV1             EV2          Runx1         Runx2         Runx3 
 
 
Figure 4.3: Runx Proteins do not Affect Global Protein Synthesis in 
Chondrogenic Cells 
(A) Percent of 35S incorporation into wild type or Runx2 -/- MEFs after a 30-
minute 35S-Met pulse.  Graph represents one independent experiment, error bars 
represent standard deviation of triplicate samples.  (B) Quantitation of 
autoradiograph shown in (C). (C) Autoradiograph of 35S incorporation into ATDC5 
cells transfected with empty vector controls (EV1 = backbone for Runx1 and 
Runx3 overexpression, EV2 = backbone for Runx2 overexpression), Runx1, 
Runx2 or Runx3 protein.   
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A.             Runx Knockdown             B.     Ribosomal RNA Transcripts
 
 
Figure 4.4: Runx2 Downregulation does not affect Levels of Protein 
Synthesis Machinery 
(A) Western blot showing knockdown of Runx2 in N1511 cells.  Lane 1 – Control, 
Lane 2 – Empty Vector, Lane 3 – Runx2 shRNA. (B) Quantitative RT-PCR 
analysis of 28S and pre-rRNA transcript levels after knockdown of Runx2 in 
N1511 cells.  Values were normalized to mCox and expressed relative to control 
levels. Graph is from 1 independent experiment and error bars represent 
standard deviation of duplicate samples 
 
 
Runx Proteins are not Directly Associated with rDNA Repeats or UBF in a 
Chondrogenic Cell Line 
 To further confirm the absence of Runx control of protein synthesis in 
chondrocytes, it is necessary to demonstrate that Runx is not associated with 
ribosomal DNA repeats, or with Upstream Binding Factor (UBF) which is 
essential for the control of all RNA PolI-mediated gene transcription.  Chromatin 
immunoprecipitation analysis demonstrates that Runx proteins are not bound to 
ribosomal DNA repeats at any stage of chondrogenesis, although pulldown with 
UBF shows robust enrichment of between 3 and 7.5 fold over input levels, 
depending on the stage of chondrocyte maturation (Figure 4.5A).  In co-
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association of these two proteins is observed (Figure 4.5B).  These data together 
provide evidence that Runx proteins do not associate with protein synthesis 
machinery during chondrogenesis, indicating that global protein synthesis may 
be under the control of a different protein or group of proteins during chondrocyte 
maturation. Interestingly, pre-rRNA and 28S levels are downregulated during the 
transition from proliferating to pre-hypertrophic chondrocyte (Figure 4.5C) and 
that UBF binding to rDNA repeats follows the same pattern (Figure 4.5A).  These 
experiments are preliminary studies and were not repeated; however they may 
indicate that there are higher rates of protein synthesis in proliferating and 
hypertrophic chondrocytes when compared to pre-hypertrophic chondrocytes. 
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A.            rDNA Promoter             B.      Co-Immunoprecipitation 
C. pre-­‐rRNA 28S
D. 
 
 
 
Figure 4.5: Runx Proteins do not Associate with Protein Synthesis 
Machinery in Chondrocytes 
(A) ChIP assessing the presence of Runx proteins and UBF on rDNA repeats 
throughout chondrogenesis.  Values are expressed as enrichment over Day 0 
Input. Graph represents one independent experiment.  (B) Western blot after 
immunoprecipitation with UBF, Runx2, or an IgG control.  (C) Quantitative RT-
PCR analysis showing expression of ribosomal biogenesis markers during 
ATDC5 differentiation.  Values are normalized to mCOX and expressed relative 
to day 0 values.  Graphs represent one independent experiment and error bars 
represent standard deviation of replicate samples. (D) Western blot data showing 
pulldown of Runx1 (top) and Runx3 (Bottom) using various Runx antibodies 
under ChIP conditions.  Antibodies used for pulldown are as follows:  Runx1; 
Lane 1 – IgG, Lane 2 – Calbiochem Anti-AML1/RHD (Ab-2), Lane 3 – Cell 
Signaling Technologies AML1 #4334, Lane 4 – Active Motif AML1 # 39000, Lane 
5 – Abcam Runx1 ab50541, Lane 6 – Blank. Runx3; Lane 1 – IgG, Lane 2 
Abnova Runx3 #11905, Lane 3 – Abnova Runx3 #49117, Lane 4 – Oncogene 
AML2 Ab1, Lane 5 – Abcam Runx1 ab50541, Lane 6 – Santa Cruz Runx3 H50. 
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Runx2 forms distinct foci on metaphase chromosomes. 
All three Runx proteins epigenetically regulate their target genes by remaining 
bound to their promoters throughout mitosis (Runx1 in hematopoietic cells, 
Runx2 in osteoblasts, and Runx3 in intestinal cells) [122, 123, 134].  To 
determine if this phenomenon occurs in chondrocytes, immunoflourescense 
analysis was done on confluent ATDC5 cells to visualize mitotic cells in an 
untreated proliferating culture.  Figure 4.6 shows ATDC5 cells during interphase 
or mitosis, after immunostaining with an antibody to either Runx1, 2 or 3.  
Despite punctate foci in interphase cells (bottom panel) neither Runx1 nor Runx3 
remains bound to chromosomes during mitosis (top panel); however, distinct 
Runx2 foci are observed on mitotic chromosomes (Figure 4.6), indicating that 
Runx2, but not Runx1 or Runx3, is in a position to epigenetically regulate its 
target genes in a chondrogenic cell line by remaining bound to its target genes 
throughout the cell cycle, potentially poising then for transcription upon exit from 
mitosis. 
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A.                                  Runx Immunofluorescense 
 
 
B.                                      Runx2 Metaphase Spread 
 
Figure 4.6: Runx2, but not Runx1 or Runx3, remains Bound to DNA during 
Mitosis 
(A) Immunoflourescense of ATDC5 cells in mitosis (top panel) or interphase 
(bottom panel).  Note the presence of Runx proteins [95] in interphase nuclei but 
the absence of Runx1 and Runx3 from mitotic chromosomes (blue=DAPI to 
detect chromosomes (B) Metaphase spread of N1511 cells showing distinct foci 
of Runx2 [95] on mitotic chromosomes (blue).   
 
94
Conclusion 
These preliminary experiments were conducted to determine an appropriate cell 
line for the study of protein synthesis control by Runx proteins during 
chondrogenesis.  In a number of in vitro chondrogenic systems, Runx proteins do 
not control global protein synthesis.  Although no changes in protein synthesis 
are observed in ATDC5 cells, this observation cannot be generalized to the 
regulation of protein synthesis and proliferation in vivo.  ATDC5 cells are derived 
from a teratocarcinoma [137], a cell line in which cell cycle regulation is already 
disrupted.  The Runx2 knockdown studies were done on N1511 cells, a 
chondrocyte cell line derived from the rib cartilage of p53-/- mice [135].  Since 
p53 is able to inhibit protein synthesis, the absence of p53 may result in 
increased global protein synthesis rates in this cell line at baseline [140]. This 
may be why Runx2 knockdown did not affect protein synthesis rates in this cell 
line.  The observation that MEFs derived from Runx2-/- mice have similar protein 
synthesis rates to wild type MEFs is consistent with the observation that 
proliferation rates are similar in wild type and Runx2-/- MEFs [141].  Thus, while 
Runx proteins do not control protein synthesis or cell proliferation in these in vitro 
chondrogenic culture systems, one cannot rule out the possibility that they 
regulate cell proliferation and protein synthesis in vivo.  These studies may be 
more appropriate using primary chondrocytes.     
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 During chondrocyte differentiation, pre-rRNA and 28S levels are 
downregulated during the transition from proliferating to pre-hypertrophic 
chondrocyte (Figure 4.5C).  This is consistent with decreased binding of UBF to 
rDNA repeats (Figure 4.5A).  Upon differentiation into hypertrophic-like 
chondrocytes, UBF binding to rDNA repeats is restored to the levels found in 
proliferating chondrocytes, and pre-rRNA and 28S levels are increased 2 fold 
over those of proliferating chondrocytes.  This demonstrates that, in 
chondrocytes, levels of protein synthesis machinery are higher in proliferating 
and hypertrophic-like chondrocytes than they are in pre-hypertrophic 
chondrocytes.  To correlate this finding with actual rates of protein synthesis, 
these experiments need to be repeated, and 35S incorporation assays can be 
done on proliferating and hypertrophic chondrocytes to determine protein 
synthesis rates at each stage of chondrogenesis, in a cell that expresses the 
normal complement of proteins found in hypertrophic chondrocytes.   
Exploratory studies designed to assess the presence of Runx proteins on 
metaphase chromosomes generated a promising result.  Runx2 remained bound 
to chromosomes throughout the cell cycle in chondrocyte cell lines.  Thus, Runx2 
is in a position to serve an epigenetic function by “bookmarking” its target genes 
for transcription upon exit from mitosis. Further studies need to be carried out to 
determine exactly where Runx2 is bound, and whether or not it confers specific 
histone modifications to repress these target genes in proliferating chondrocytes 
while enhancing expression of genes at the hypertrophic stage.  
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CHAPTER V: 
Discussion 
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Summary 
This dissertation characterizes the expression of Runx1 in normal articular and 
osteoarthritic cartilage.  The major findings of my thesis studies are the robust 
expression of Runx1 in superficial zone chondrocytes of articular cartilage, the 
physiological response of Runx1 to mechanical compression, and the expression 
of Runx1 in cells that form clusters in response to cartilage damage.  In these 
chondrocyte populations, Runx1 is co-expressed with markers for mesenchymal 
progenitor cells, alluding to a possible protective role in cartilage tissue.   
Additionally, Runx1 is associated with markers of proliferation in OA cartilage. It 
appears that when cartilage tissue is damaged, a response occurs in Runx1 
positive cells that have the potential to repopulate the surface.  In pursuit of a 
molecular basis for these functions, the thesis studies addressed the potential for 
Runx1 in regulatory protein synthesis in chondrocytes.   Using a candidate gene 
approach, many genes that are expressed during chondrogenesis were identified 
as having the potential to be regulated by Runx genes based on their promoter 
analysis.  However, the small number of candidate genes chosen were not 
differentially regulated in response to the overexpression of Runx1 in a 
chondrocyte cell line.   
 Preliminary experiments were carried out to determine if Runx proteins 
have novel functions in chondrocytes; namely, global protein synthesis control 
and epigenetic regulation of target genes.  Preliminary experiments in 3 different 
chondrocyte cell lines failed to associate Runx transcription factors with protein 
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synthesis control, indicating that either a better chondrocyte model should be 
used, or that a different transcription factor is responsible for protein synthesis 
control in the chondrocyte.  Interestingly, a pilot study characterizing the 
expression of Runx proteins throughout the cell cycle in proliferating 
chondrocytes showed that Runx2 remains bound to mitotic chromosomes, 
indicating a possible epigenetic function of Runx2 in chondrocytes by 
“bookmarking” target genes for transcription upon entry into S phase.  
 
The Expression of Runx1 in Superficial Zone Chondrocytes 
A number of studies show that Runx1 is detected in pre-chondrocytes, in the 
mesenchymal condensations of developing cartilage tissue, in suture lines of the 
calvaria, and in the periosteum [75, 77, 78, 142]. In addition, Runx1 is also the 
only Runx protein expressed in the chondrocytes of permanent cartilage 
structures (articular cartilage, hyoid cartilage, xyphoid process) during 
development [75, 143]. Although Runx1 is essential for hematopoietic cell 
differentiation, and various mutations in the gene result in leukemias [83], the 
expression of Runx1 in cartilage tissue suggests a unique, non-hematopoietic, 
functional role for the protein.  The studies carried out in this dissertation show 
that Runx1 is expressed in the superficial zone chondrocytes of normal articular 
cartilage, which is similar to its expression in epithelial linings [103]. The most 
robust Runx1 expression was restricted to the superficial zone, the 1-2 cell layer 
that is closest to the articular cartilage surface.  This surface cell layer is different 
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from the middle and deep zones of articular cartilage in both morphology with 
respect to organization of collagen fibrils, and gene expression [97]. When 
cultured, cells of the superficial zone have higher rates of proliferation than cells 
of the deep and middle zones [92].  In addition, these superficial zone cells have 
been shown to express markers of mesenchymal progenitor cells such as Notch-
1, Endoglin (CD105), ALCAM (CD166), and VCAM-1 (CD106) [97-99], although, 
other than VCAM-1, the co-expression of these other proteins with Runx1 in 
superficial zone chondrocytes was not performed.  Runx1 is robustly expressed 
in the superficial zone cells and, in part, may be responsible for maintaining the 
phenotype of these cells.  Laser capture microdissection is a technique that 
allows for very small amounts of tissue to be dissected and analyzed.  Using this 
technique to separate superficial, middle, and deep zones of articular cartilage 
combined with RT-PCR and microarray analysis, it should be possible to identify 
genes that are present in each zone and quantitate the expression levels of 
Runx1, as well as MSC markers, in each of the zones.   
 
Runx1 Expression in Osteoarthritic Cartilage 
 In human OA cartilage, an increase in Runx1 protein levels was observed 
on the medial side of a varus knee joint, which had damaged cartilage.  It has 
been shown that varying degrees of varus alignment are mirrored by significant 
differences in medial and lateral stress distribution [144].  As stated previously, 
varying degrees of mechanical stress cause upregulation of a number of genes 
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that contribute to the pathogenesis of OA [23, 25]. Additionally, Runx1 is 
upregulated in response to mechanical loading in an ex vivo compression model 
using bovine articular cartilage.  Many studies have documented changes in 
gene expression in response to articular cartilage compression, with genes 
differentially expressed under both dynamic and static compression conditions 
[33, 145-148].  While the expression of Runx1 under dynamic compression 
conditions was not studied, Runx1 mRNA is increased in as little as 6 hours after 
the induction of excess loads of static compression (Figure 2.2B).  This finding is 
consistent with several previous studies showing the upregulation of pro-
inflammatory cytokines and matrix metalloproteases (MMPs) under loading 
conditions [33, 149].   It is also known that under compression conditions cell 
proliferation is increased [100].  MMPs are direct transcriptional targets of Runx 
proteins [86]. Runx1 also activates genes that support cell differentiation and 
phenotype maintenance [83].  Thus, compression stimulated upregulation of 
Runx1 could either contribute to cartilage degeneration or potentially promote 
expansion of a progenitor cell population in an attempt to repopulate damaged 
cartilage as documented in previous studies, or both [150].  
Striking changes in the expression and distribution of Runx1-positive cells 
were found in human OA and during disease progression in a mouse model of 
OA.  This provides insight into possible mechanisms related to both degradation 
and attempted repair of damaged cartilage. Runx1 is expressed in “chondrocyte 
clones” in human OA and at lesion borders in damaged tissue, rather than a 
101
general upregulation in all chondrocytes of diseased cartilage.  Taken together, 
this expression pattern and the localization of Runx1 in the articular surface of 
normal cartilage suggests a function in protecting surface integrity and an 
attempt to increase chondrocyte numbers at the border of degenerating cartilage.  
Consistent with findings in human patients, the same pattern of Runx1 is 
observed in OA-like lesions in the mouse model.  When monitored during 
disease progression, Runx1 first decreases in the immediate area of the 
developing lesion prior to cartilage fibrillation and degeneration.  Following this 
stage, Runx1 positive clusters begin to form at the periphery of the spreading 
lesion.  Given these findings, it is reasonable to hypothesize that Runx1 serves a 
protective function rather than contributing to cartilage degradation.  Its 
association with MSC markers its and localization at the periphery of OA 
suggests that it is involved in cartilage regeneration.  Further studies need to be 
done to elicit the exact role of Runx1 in OA cartilage.  The most beneficial studies 
would involve inducing OA in mice overexpressing Runx1 in cartilage, or in mice 
with Runx1 absent from cartilage, to determine the progression of OA under the 
influence of altered Runx1 levels.  If the above hypothesis is correct, mice with 
Runx1 upregulated in articular cartilage would show decreased progression of 
OA lesions when compared to wild-type mice, while mice lacking Runx1 in 
cartilage would show enhanced development of these lesions.  
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Runx1 Association with Proliferation and MSC Markers in OA Cartilage 
The localization of Runx1 in both diseased OA cartilage and in normal cartilage is 
consistent with the expression of other markers that have been well 
characterized. Additionally, certain osteoarthritic “clones” have been shown to 
express markers for mesenchymal progenitor cells, including VCAM-1[96, 100, 
101].  In mouse articular cartilage, VCAM-1 and Runx1 are co-expressed in 
chondrocytes in normal superficial zone cells as well as in chondrocyte clones in 
damaged tissue. These clones have also been shown to represent a proliferative 
cell population [20, 102]. Interestingly, these Runx-1, VCAM-1 expressing 
chondrocytes in OA cartilage also express proliferation markers such as PCNA 
and Ki-67.   Together, these data indicate that the increase in Runx1 positive 
chondrocytes in osteoarthritic cartilage represents a proliferative response of a 
progenitor cell population in response to cartilage damage.  However, in vitro 
studies in chondrocyte cell lines did not show a proliferative response to the 
overexpression of Runx1.  This may be because the cell line that was used was 
derived from a mouse embryonal carcinoma and proliferated rapidly in 
monolayer.  These cells were chosen because they represented a well-
differentiated chondrocyte in culture, expressing high levels of Sox9.  In contrast 
to N1511 cells, ATDC5 cells are not known to be deficient in p53, making them a 
more ideal cell line in which to study proliferation.  Other studies in our laboratory 
show that Runx1 deficiency results in decreased proliferation in MEFs.  This, 
taken with the characterization of Runx1 being co-expressed with markers for 
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mesenchymal progenitor cells, suggests that Runx1 may have a role in 
proliferation in chondroprogenitor cells, but not in committed chondrocytes.  To 
confirm this, the MEF studies should be repeated.  Additionally, overexpression 
and knockdown of Runx1 in primary chondrocytes may be able to induce 
changes in proliferation rates. 
In contrast to the concept that the clones represent a proliferation of 
superficial zone cells, recent studies have suggested that cell clusters in lacunae 
near OA lesions represent migrated cells [151]. Reminiscent of mesenchymal cell 
condensations in forming neocartilage (e.g. the embryo anlagen), in which the 
cells express Runx1, the clones may represent both proliferating and migrated 
progenitor cells that are attempting to either limit the OA lesion or re-establish the 
normal cartilage border. Of interest, Runx1 has a role in the regulation of stem 
cell recruitment and proliferation for regeneration of hematopoietic stem cells and 
hair follicle stem cells [107, 152].  The finding of robust expression of Runx1 in a 
population of mesenchymal progenitor cell clusters suggests that Runx1 
functions as a compensatory mechanism rather than a matrix-degrading 
component in response to compressive forces.   
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Protein Synthesis Control in the Chondrocyte 
Although Runx1, Runx2, and Runx3 all bind to rDNA repeats known to regulate 
ribosomal gene transcription, preliminary experiments show that this novel 
mechanism of protein synthesis control does not take place in a number of 
chondrogenic cell lines in vitro.  Recently, it was observed that other cell fate 
determining transcription factors regulate global protein synthesis in certain cell 
types.  In myocytes, protein synthesis is regulated by the transcription factors 
MyoD and Mgn while in adipocytes it is regulated by C/EBP?[153].  If cell fate 
determining transcription factors are responsible for protein synthesis regulation 
in their respective cell types, it would follow that either Sox9 or Sox5/6 regulate 
protein synthesis during chondrocyte maturation.   
 The dynamic nature of the chondrocyte involves the transition from 
proliferation to hypertrophy with a subset of stage-specific genes expressed at 
each stage of chondrocyte maturation.  Sox9 is expressed in proliferating 
chondrocytes, but is downregulated during chondrocyte hypertrophy.  If Sox9 
were responsible for protein synthesis control at the onset of chondrogenesis, 
another transcription factor would have to take over upon downregulation of 
Sox9.  The likely candidate for this is Runx2, as it is the transcription factor that is 
most important for the transition to chondrocyte hypertrophy.   
 The fact that Runx2-/- mice still exhibit hypertrophic chondrocytes in the 
tibia/fibula and radius/ulna, but Runx2/Runx3 double knockouts completely lack 
hypertrophic chondrocytes [67] suggests a functionally redundant role for these 
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proteins in the hypertrophic chondrocyte.  It is possible that upon downregulation 
of Runx2, Runx3 is able to take over protein synthesis control, and this is why a 
phenotype is not seen upon downregulation of only Runx2.  To test this 
hypothesis, these experiments can be repeated with Runx2/Runx3 double 
knockout cells.  Additionally, all overexpression experiments were done in 
proliferating chondrocytes, where it is possible that Sox9 is in control of protein 
synthesis.   This set of experiments can be repeated by overexpressing Sox9 in 
chondrocyte cell lines to assess changes in rates of global protein synthesis and 
levels of protein synthesis machinery.  The lack of Runx2 or Runx3 binding to 
rDNA repeats in hypertrophic chondrocytes suggests that neither Runx2 nor 
Runx3 regulate rDNA transcription during chondrocyte hypertrophy.  However, 
this one observation is not enough to rule out the possibility that they contribute 
to global protein synthesis control during late stage chondrogenesis. 
 Because there are few good cell models for culturing primary 
chondrocytes and maintaining them as either proliferating or hypertrophic 
chondrocytes, the protein synthesis question is one that is difficult to assess.  A 
combination of laser capture microdissection with chromatin immunoprecipitation 
would determine if Runx proteins were bound to rDNA promoters in each 
subpopulation of chondrocytes.  Additionally, ChIP experiments on MEFs 
undergoing chondrogenic differentiation in micromass cultures can be done to 
determine which transcription factors bind rDNA repeats at each stage of 
chondrogenesis.  Again, since ATDC5 cells are not derived from a primary 
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chondrocyte source, regulation of protein synthesis control may be altered in this 
cell line.  While this cell line was an appropriate choice for preliminary 
experiments because of the ease of transfection and committed chondrocyte 
phenotype, negative results must be confirmed in primary chondrocytes.   
 
Runx and Epigenetics in the Chondrocyte 
In interphase ATDC5 cells, Runx1, 2, and 3 all exhibit characteristic distribution 
in punctate foci throughout the nucleus.  In stark contrast, mitotic chromosomes 
exhibit complete absence of Runx1 and Runx3, while Runx2 foci persist 
throughout mitosis.  In addition to epigenetically regulating target genes by 
controlling histone modifications, the retention of Runx2 on its target genes 
throughout mitosis is hypothesized to be a novel epigenetic mechanism by which 
target genes are poised for transcription upon exit from mitosis [134].   Although 
most known Runx2 chondrogenic target genes are expressed in post-proliferative 
hypertrophic chondrocytes, Runx2 is found on mitotic chromosomes in a 
committed, but proliferating chondrocyte.  Although it is not known exactly which 
genes Runx2 is bound to during mitosis in ATDC5 or N1511 cells, it is possible 
that Runx2 is on the promoters of genes involved in chondrocyte hypertrophy, 
poising them for transcription upon exit from the cell cycle and entry into the 
hypertrophic stage of chondrocyte maturation. The binding of a transcription 
factor to genes in proliferating chondrocytes, although they are not expressed 
until hypertrophy, would represent an entirely new level of epigenetic regulation. 
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FISH experiments would be able determine the genes that are associated with 
the Runx foci on mitotic chromosomes, first by identifying the specific 
chromosomes to which Runx2 is bound, then by designing specific probes to 
Runx target genes known to reside on those chromosomes.  The absence of 
Runx1 and Runx3 on the metaphase chromosomes of these chondrogenic cell 
lines suggests that these proteins may not function to “bookmark” genes as a 
means of epigenetic regulation.  This is not to say that Runx1 and Runx3 do not 
function epigenetically in chondrocytes.  It is possible that all three Runx proteins 
confer specific histone modifications to their target genes in chondrocytes.  This 
hypothesis can be tested with ChIP on Chip experiments.  As in regular 
chromatin immunoprecipitation experiments, Runx proteins would be crosslinked 
with the DNA sequences to which they were bound and isolated by 
immunoprecipitation.  Instead of analyzing the chromatin by RT-PCR, the 
chromatin can be subjected to microarray analysis to determine direct targets of 
Runx proteins in chondrogenesis.  When target genes are identified, ChIP/re-
ChIP experiments can be done, first using a Runx antibody for 
immunoprecipitation, and then using a modified histone antibody to determine 
the specific histone modifications with which Runx proteins are associated on the 
promoters of their target genes.  To further ascertain the role of Runx proteins in 
conferring specific histone modifications in chondrocytes, knockdown studies can 
be performed to determine if the specific histone modifications identified in the 
presence of Runx proteins still persist in their absence.   
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Conclusions 
 This dissertation characterized the expression of Runx1 in normal and 
osteoarthritic cartilage, and began to explore potential functions of Runx1 in 
healthy cartilage and during disease states.  Identification of downstream Runx1 
target genes, in addition to experimental induction of osteoarthritis in mice either 
deficient in or overexpressing Runx1 in cartilage, will help ascertain whether 
Runx1 has a protective effect in cartilage.  Additionally, identifying the novel 
mechanisms by which Runx proteins regulate cartilage maturation will give a 
greater understanding of the molecular mechanisms that differentiate growth 
plate chondrocytes from articular chondrocytes, as well as characterizing 
different sub-populations of articular chondrocytes that may respond differently to 
the cartilage damage that is characteristic of osteoarthritis.  A greater 
understanding of the contribution of Runx proteins to chondrogenesis could lead 
to the discovery of potential drug targets to attenuate the severity of cartilage 
disease, decreasing the need for surgery and improving the quality of life for 
people with disorders involving chondrocyte misregulation.    
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